1149 lines
173 KiB
Text
1149 lines
173 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK1129">
|
|
<meta name="ncbi_domain" content="gene">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK1129/?report=reader">
|
|
<meta name="ncbi_pagename" content="Long QT Syndrome Overview - GeneReviews® - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Long QT Syndrome Overview - GeneReviews® - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/gene/loeys-dietz/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/gene/lchad/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/gene/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="GeneReviews® [Internet]">
|
|
<meta name="citation_title" content="Long QT Syndrome Overview">
|
|
<meta name="citation_publisher" content="University of Washington, Seattle">
|
|
<meta name="citation_date" content="2024/03/21">
|
|
<meta name="citation_author" content="Alexander J Groffen">
|
|
<meta name="citation_author" content="Hennie Bikker">
|
|
<meta name="citation_author" content="Imke Christiaans">
|
|
<meta name="citation_pmid" content="20301308">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1129/">
|
|
<meta name="citation_keywords" content="Calmodulin">
|
|
<meta name="citation_keywords" content="Calmodulin-3">
|
|
<meta name="citation_keywords" content="Caveolin-3">
|
|
<meta name="citation_keywords" content="Inward rectifier potassium channel 2">
|
|
<meta name="citation_keywords" content="Potassium voltage-gated channel subfamily E member 1">
|
|
<meta name="citation_keywords" content="Potassium voltage-gated channel subfamily E member 2">
|
|
<meta name="citation_keywords" content="Potassium voltage-gated channel subfamily KQT member 1">
|
|
<meta name="citation_keywords" content="Sodium channel protein type 5 subunit alpha">
|
|
<meta name="citation_keywords" content="Triadin">
|
|
<meta name="citation_keywords" content="Voltage-dependent L-type calcium channel subunit alpha-1C">
|
|
<meta name="citation_keywords" content="Voltage-gated inwardly rectifying potassium channel KCNH2">
|
|
<meta name="citation_keywords" content="CACNA1C">
|
|
<meta name="citation_keywords" content="CALM1">
|
|
<meta name="citation_keywords" content="CALM2">
|
|
<meta name="citation_keywords" content="CALM3">
|
|
<meta name="citation_keywords" content="CAV3">
|
|
<meta name="citation_keywords" content="KCNE1">
|
|
<meta name="citation_keywords" content="KCNE2">
|
|
<meta name="citation_keywords" content="KCNH2">
|
|
<meta name="citation_keywords" content="KCNJ2">
|
|
<meta name="citation_keywords" content="KCNQ1">
|
|
<meta name="citation_keywords" content="SCN5A">
|
|
<meta name="citation_keywords" content="TRDN">
|
|
<meta name="citation_keywords" content="Long QT Syndrome">
|
|
<meta name="citation_keywords" content="Overview">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Long QT Syndrome Overview">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="University of Washington, Seattle">
|
|
<meta name="DC.Contributor" content="Alexander J Groffen">
|
|
<meta name="DC.Contributor" content="Hennie Bikker">
|
|
<meta name="DC.Contributor" content="Imke Christiaans">
|
|
<meta name="DC.Date" content="2024/03/21">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1129/">
|
|
<meta name="description" content="The purpose of this overview is to:">
|
|
<meta name="og:title" content="Long QT Syndrome Overview">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="The purpose of this overview is to:">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1129/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/gene/rws/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1129/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D93FB7C8765710000000000F400D1.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK1129/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/gene/loeys-dietz/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Long QT Syndrome Overview</div><div class="j">GeneReviews® [Internet]</div></div><div class="tail"><a href="/books/n/gene/lchad/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK1129/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK1129/&text=Long%20QT%20Syndrome%20Overview"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/gene/?report=reader">Title Information</a><a href="/books/n/gene/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK1129/?report=classic">Switch to classic view</a><a href="/books/NBK1129/pdf/Bookshelf_NBK1129.pdf">PDF (545K)</a><a href="/books/NBK1129/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK1129%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D93FB7C8765710000000000F400D1.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK1129_"><span class="title" itemprop="name">Long QT Syndrome Overview</span></h1><p class="contribs">Groffen AJ, Bikker H, Christiaans I.</p><p class="fm-aai"><a href="#_NBK1129_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 34 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="rws.Summary" itemprop="description"><h2 id="_rws_Summary_">Summary</h2><p>The purpose of this overview is to:</p><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><p class="no_top_margin">Briefly describe the <a href="#rws.Clinical_Characteristics_of_Long_QT">clinical characteristics</a> of long QT syndrome (LQTS);</p></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><p class="no_top_margin">Review the <a href="#rws.Genetic_Causes_of_Long_QT_Syndrome">genetic causes</a> of LQTS;</p></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><p class="no_top_margin">Review the <a href="#rws.Differential_Diagnosis_of_Long_QT_Sy">differential diagnosis</a> of LQTS with a focus on genetic conditions;</p></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><p class="no_top_margin">Provide an <a href="#rws.Evaluation_Strategies_to_Identify_th">evaluation strategy</a> to identify the genetic cause of LQTS in a proband (when possible);</p></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><p class="no_top_margin">Review <a href="#rws.Management">management</a> of LQTS including targeted pharmacologic treatment;</p></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><p class="no_top_margin">Inform <a href="#rws.Genetic_Risk_Assessment_and_Evaluati">risk assessment</a> and evaluation of at-risk relatives for early detection and treatment of LQTS.</p></dd></dl></dl>
|
|
</div><div id="rws.Clinical_Characteristics_of_Long_QT"><h2 id="_rws_Clinical_Characteristics_of_Long_QT_">1. Clinical Characteristics of Long QT Syndrome</h2><p>Long QT syndrome (LQTS) is characterized by QT prolongation and T wave abnormalities on EKG. LQTS predisposes individuals to a significant risk of life-threatening arrhythmic events, especially in young individuals. Molecular genetic testing identifies a genetic cause in ~80% of affected individuals, most often in genes associated with autosomal dominant LQTS. Subsequent cascade genetic testing allows for identification of at-risk relatives who can benefit from tailored therapeutic management strategies to reduce morbidity and mortality.</p><p>The initial scoring system for a clinical diagnosis of LQTS was updated by <a class="bibr" href="#rws.REF.schwartz.2011.2181" rid="rws.REF.schwartz.2011.2181">Schwartz & Crotti [2011]</a> and mainly relied on EKG findings, of which a prolonged corrected QT interval was the most prominent. This scoring system did not account for genetic test results. Nevertheless, the detection of a pathogenic variant proven to cause LQTS is also sufficient to establish a diagnosis of LQTS [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>]. This idea is incorporated in the LQTS diagnostic scoring system proposed in the European Society of Cardiology guidelines for management of LQTS [<a class="bibr" href="#rws.REF.zeppenfeld.2022.3997" rid="rws.REF.zeppenfeld.2022.3997">Zeppenfeld et al 2022</a>] (see <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_scoring_system_fo/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromescoringsystemfo">Table 1</a>). A LQTS risk score of >3.0 in the absence of a secondary cause for QT prolongation is sufficient for a diagnosis of LQTS.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figrwsTlongqtsyndromescoringsystemfo"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_scoring_system_fo/?report=objectonly" target="object" title="Table 1. " class="img_link icnblk_img" rid-ob="figobrwsTlongqtsyndromescoringsystemfo"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="rws.T.long_qt_syndrome_scoring_system_fo"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_scoring_system_fo/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromescoringsystemfo">Table 1. </a></h4><p class="float-caption no_bottom_margin">Long QT Syndrome: Scoring System for Clinical Diagnosis </p></div></div><div id="rws.Cardiac_Features"><h3>Cardiac Features</h3><p>T wave abnormalities include T wave alternans, notched T wave, broad-based and flattened T waves (see <a class="bibr" href="#rws.REF.adler.2020.418" rid="rws.REF.adler.2020.418">Adler et al [2020]</a> and <a class="bibr" href="#rws.REF.wilde.2022.332" rid="rws.REF.wilde.2022.332">Wilde et al [2022]</a> for concise examples and <a class="bibr" href="#rws.REF.tardo.2023.e13015" rid="rws.REF.tardo.2023.e13015">Tardo et al [2023]</a> for a comprehensive review) and are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating and may cause palpitations, dizziness, or syncope, the most common symptom in individuals with LQTS. Syncope is typically precipitous and without warning. A careful evaluation of medical history can help distinguish LQTS-associated syncope from common vasovagal and orthostatic forms of syncope in which presyncope and other warning symptoms occur. Absence of aura, incontinence, and postictal findings help differentiate LQTS-associated syncope from seizures. The number of syncopal events in symptomatic individuals ranges from one to hundreds, averaging just a few. In some instances, TdP degenerates to ventricular fibrillation and aborted cardiac arrest (if the individual is defibrillated) or sudden death.</p><p>Cardiac events (i.e., syncope, cardiac arrest, or sudden cardiac death) may occur from infancy through middle age but are most common from the preteen years through the 20s, with the risk generally diminishing throughout that time period. The usual age range of events differs somewhat for each genotype. Cardiac events are uncommon after age 40 years; when present, they are often triggered by administration of a QT-prolonging drug or hypokalemia. Cardiac events in individuals older than age 40 years are more likely associated with <i>SCN5A</i>-related LQTS.</p><p>Pathogenic variants in <i>KCNH2</i>, <i>KCNQ1</i>, and <i>SCN5A</i> account for 90% of individuals with an identified molecular cause of LQTS. Three clinical phenotypes are recognized in individuals with pathogenic variants in these genes (see <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_phenotype_correla/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromephenotypecorrela">Table 2</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figrwsTlongqtsyndromephenotypecorrela"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_phenotype_correla/?report=objectonly" target="object" title="Table 2. " class="img_link icnblk_img" rid-ob="figobrwsTlongqtsyndromephenotypecorrela"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="rws.T.long_qt_syndrome_phenotype_correla"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_phenotype_correla/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromephenotypecorrela">Table 2. </a></h4><p class="float-caption no_bottom_margin">Long QT Syndrome: Phenotype Correlations by Gene </p></div></div><p>Although incidence of syncopal events is highest in those with <i>KCNQ1</i>-related LQTS and lowest in <i>SCN5A</i>-related LQTS, the incidence of sudden cardiac arrest or death was highest in individuals with <i>SCN5A</i>-related LQTS in a cohort of individuals with an identified genetic cause from the LQTS Registry receiving treatment (see <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_phenotype_correla/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromephenotypecorrela">Table 2</a>). Of individuals who die of complications of LQTS, death is the first sign of the disorder in an estimated 10%-15%.</p><p>The risk of sudden cardiac death is dependent on history of syncope, proband status (i.e., being the first in the family in whom the genetic cause for LQTS has been identified), QTc interval, treatment, age, and sex. The age and sex dependency differs between the three main molecular causes of LQTS. Overall, boys are at relatively high risk before onset of adolescence, and girls after the onset of adolescence (age 13 to 14 years) [<a class="bibr" href="#rws.REF.wang.2022.988951" rid="rws.REF.wang.2022.988951">Wang et al 2022</a>].</p><ul><li class="half_rhythm"><div><b><i>KCNH2</i>-related LQTS.</b> Increased mortality occurred especially in women older than age 12 to 13 years, particularly up to nine months postpartum [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>, <a class="bibr" href="#rws.REF.skinner.2019.22" rid="rws.REF.skinner.2019.22">Skinner et al 2019</a>]. The risk for males aged one to 13 years can also be high [<a class="bibr" href="#rws.REF.wang.2022.988951" rid="rws.REF.wang.2022.988951">Wang et al 2022</a>]. A common trigger is sudden arousal (e.g., auditory stimuli).</div></li><li class="half_rhythm"><div><b><i>KCNQ1</i>-related LQTS.</b> Severely increased mortality was observed for boys age five to 15 years [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>, <a class="bibr" href="#rws.REF.skinner.2019.22" rid="rws.REF.skinner.2019.22">Skinner et al 2019</a>], although the risk for girls age 13 to 20 years can also be high [<a class="bibr" href="#rws.REF.wang.2022.988951" rid="rws.REF.wang.2022.988951">Wang et al 2022</a>]. Most sudden cardiac deaths occur during exercise (e.g., swimming) and emotion [<a class="bibr" href="#rws.REF.wilde.2022.332" rid="rws.REF.wilde.2022.332">Wilde et al 2022</a>].</div></li><li class="half_rhythm"><div><b><i>SCN5A</i>-related LQTS.</b> Increased mortality is observed from childhood (especially in boys) throughout adulthood (both sexes) [<a class="bibr" href="#rws.REF.wang.2022.988951" rid="rws.REF.wang.2022.988951">Wang et al 2022</a>]. In contrast to <i>KCNQ1</i>- and <i>KCNH2</i>-related LQTS, QT prolongation in <i>SCN5A</i>-related LQTS is more pronounced during slow heart rate and events usually occur during sleep or rest.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figrwsTcumulativeprobabilityofcardiac"><a href="/books/NBK1129/table/rws.T.cumulative_probability_of_cardiac/?report=objectonly" target="object" title="Table 3. " class="img_link icnblk_img" rid-ob="figobrwsTcumulativeprobabilityofcardiac"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="rws.T.cumulative_probability_of_cardiac"><a href="/books/NBK1129/table/rws.T.cumulative_probability_of_cardiac/?report=objectonly" target="object" rid-ob="figobrwsTcumulativeprobabilityofcardiac">Table 3. </a></h4><p class="float-caption no_bottom_margin">Cumulative Probability of Cardiac Events by Age </p></div></div><p>LQTS exhibits reduced penetrance for EKG changes and symptoms. Approximately 25% of individuals with an identified molecular cause of LQTS have a normal QTc (<440 ms) on baseline EKG. The percentage of individuals with a normal QTc was higher in those with <i>KCNQ1</i>-related LQTS (36%) than in those with <i>KCNH2</i>-related LQTS (19%) or <i>SCN5A</i>-related LQTS (10%) [<a class="bibr" href="#rws.REF.priori.2003.1866" rid="rws.REF.priori.2003.1866">Priori et al 2003</a>, <a class="bibr" href="#rws.REF.goldenberg.2011.51" rid="rws.REF.goldenberg.2011.51">Goldenberg et al 2011</a>]. With appropriate treatment, at least 56% of individuals with <i>KCNQ1</i>-related LQTS, 51% of those with <i>KCNH2</i>-related LQTS, and 59% of those with <i>SCN5A</i>-related LQTS remain asymptomatic (assessed at age 50 years) [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>].</p></div><div id="rws.NonCardiac_Features"><h3>Non-Cardiac Features</h3><p>Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia.</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/acpp/?report=reader">Andersen-Tawil syndrome</a>, caused by a heterozygous pathogenic variant in <i>KCNJ2</i>, is associated with prolonged QT interval, episodic muscle paralysis, muscle weakness, facial dysmorphism, dental anomalies, and small hands and feet.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/jln/?report=reader">Jervell and Lange-Nielsen syndrome</a>, caused by biallelic <i>KCNQ1</i> or <i>KCNE1</i> pathogenic variants, is associated with congenital profound sensorineural hearing loss and QTc usually >500 ms.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/timothy/?report=reader">Timothy syndrome</a>, caused by a heterozygous pathogenic variant in <i>CACNA1C</i>, is a multisystem disorder where QTc prolongation causes a high risk of arrhythmic events in neonates. Extracardiac features include hand/foot syndactyly, neurodevelopmental features including autism spectrum disorder and intellectual disability, and characteristic facial appearance.</div></li></ul></div><div id="rws.Biallelic_Pathogenic_Variants__Digen"><h3>Biallelic Pathogenic Variants / Digenic Inheritance</h3><p>LQTS associated with biallelic pathogenic variants (in genes associated with autosomal dominant LQTS) or heterozygosity for pathogenic variants in two different genes (i.e., digenic pathogenic variants) is generally associated with a more severe phenotype with longer QTc interval and a higher incidence of cardiac events [<a class="bibr" href="#rws.REF.schwartz.2003.1120" rid="rws.REF.schwartz.2003.1120">Schwartz et al 2003</a>, <a class="bibr" href="#rws.REF.westenskow.2004.1834" rid="rws.REF.westenskow.2004.1834">Westenskow et al 2004</a>, <a class="bibr" href="#rws.REF.tester.2005.507" rid="rws.REF.tester.2005.507">Tester et al 2005</a>, <a class="bibr" href="#rws.REF.itoh.2010.1411" rid="rws.REF.itoh.2010.1411">Itoh et al 2010</a>, <a class="bibr" href="#rws.REF.mullally.2013.378" rid="rws.REF.mullally.2013.378">Mullally et al 2013</a>].</p></div><div id="rws.Nomenclature"><h3>Nomenclature</h3><p>The designation "acquired long QT syndrome" may be used to distinguish QT interval prolongation associated with non-heritable causes and conditions from heritable predisposition to QTc prolongation. Of note, gene-environment interactions occur, and drug exposures and conditions associated with acquired LQTS may also be cardiac event triggers in individuals with a genetic predisposition to QT prolongation.</p></div><div id="rws.Prevalence"><h3>Prevalence</h3><p>The prevalence of LQTS has been estimated at 1:2,500 [<a class="bibr" href="#rws.REF.schwartz.2009.113" rid="rws.REF.schwartz.2009.113">Schwartz et al 2009</a>, <a class="bibr" href="#rws.REF.giudicessi.2013.417" rid="rws.REF.giudicessi.2013.417">Giudicessi & Ackerman 2013</a>, <a class="bibr" href="#rws.REF.lieve.2015.ii1" rid="rws.REF.lieve.2015.ii1">Lieve & Wilde 2015</a>].</p></div></div><div id="rws.Genetic_Causes_of_Long_QT_Syndrome"><h2 id="_rws_Genetic_Causes_of_Long_QT_Syndrome_">2. Genetic Causes of Long QT Syndrome</h2><p>Using the ClinGen Gene Curation Framework, the <a href="https://www.clinicalgenome.org/affiliation/40025/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Clinical Genome Resource Long QT Syndrome Gene Curation Expert Panel</a> has categorized reported long QT syndrome (LQTS)-related genes into definitive, strong, moderate, and limited clinical validity classification levels for LQTS, acquired LQTS, and LQTS-associated phenotypes (see <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromegeneticcauses">Table 4</a>) [<a class="bibr" href="#rws.REF.adler.2020.418" rid="rws.REF.adler.2020.418">Adler et al 2020</a>].</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figrwsTlongqtsyndromegeneticcauses"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object" title="Table 4. " class="img_link icnblk_img" rid-ob="figobrwsTlongqtsyndromegeneticcauses"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="rws.T.long_qt_syndrome_genetic_causes"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromegeneticcauses">Table 4. </a></h4><p class="float-caption no_bottom_margin">Long QT Syndrome: Genetic Causes </p></div></div></div><div id="rws.Differential_Diagnosis_of_Long_QT_Sy"><h2 id="_rws_Differential_Diagnosis_of_Long_QT_Sy_">3. Differential Diagnosis of Long QT Syndrome</h2><p><b>Other causes of QTc interval prolongation</b> to be considered:</p><ul><li class="half_rhythm"><div>Drug-induced QT prolongation (See drugs at <a href="https://www.crediblemeds.org/index.php/login/dlcheck" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">CredibleMeds<sup>®</sup></a>; free registration required.)</div></li><li class="half_rhythm"><div>Hypokalemia</div></li><li class="half_rhythm"><div>Certain neurologic conditions including subarachnoid bleed</div></li><li class="half_rhythm"><div>Structural heart disease</div></li></ul><p><b>Other causes of syncope or sudden death</b> to be considered in children and young adults:</p><ul><li class="half_rhythm"><div>Sudden infant death syndrome (SIDS), commonly defined as unexpected sudden death within the first year of life. Death during the first year of life in families with long QT syndrome (LQTS) appears to be rare, yet infants with SIDS have been shown to have pathogenic variants in one of the genes listed in <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromegeneticcauses">Table 4</a> [<a class="bibr" href="#rws.REF.ackerman.2001.2264" rid="rws.REF.ackerman.2001.2264">Ackerman et al 2001</a>, <a class="bibr" href="#rws.REF.schwartz.2001.89" rid="rws.REF.schwartz.2001.89">Schwartz et al 2001</a>, <a class="bibr" href="#rws.REF.arnestad.2007.361" rid="rws.REF.arnestad.2007.361">Arnestad et al 2007</a>]. While it seems probable that these pathogenic variants were the cause of the SIDS, the association is uncertain, and the frequency of pathogenic variants in infants with SIDS has been questioned [<a class="bibr" href="#rws.REF.wedekind.2006.129" rid="rws.REF.wedekind.2006.129">Wedekind et al 2006</a>].</div></li><li class="half_rhythm"><div>Vasovagal (neurally mediated) syncope, orthostatic hypotension</div></li><li class="half_rhythm"><div>Seizures. Absence of aura, incontinence, and postictal findings help differentiate LQTS-associated syncope from seizures.</div></li><li class="half_rhythm"><div>Familial ventricular fibrillation</div></li><li class="half_rhythm"><div>Subtle cardiomyopathies (<a href="/books/n/gene/hyper-card/?report=reader">HCM</a>, <a href="/books/n/gene/dcm-ov/?report=reader">DCM</a>, <a href="/books/n/gene/arvd/?report=reader">ARVC</a>)</div></li><li class="half_rhythm"><div>
|
|
<a href="/books/n/gene/cvt/?report=reader">Catecholaminergic polymorphic ventricular tachycardia</a>
|
|
</div></li><li class="half_rhythm"><div>Calcium release deficiency syndrome [<a class="bibr" href="#rws.REF.ormerod.2022.e003589" rid="rws.REF.ormerod.2022.e003589">Ormerod et al 2022</a>]</div></li><li class="half_rhythm"><div>
|
|
<a href="/books/n/gene/brugada/?report=reader">Brugada syndrome</a>
|
|
</div></li><li class="half_rhythm"><div>Anomalous coronary artery</div></li></ul></div><div id="rws.Evaluation_Strategies_to_Identify_th"><h2 id="_rws_Evaluation_Strategies_to_Identify_th_">4. Evaluation Strategies to Identify the Genetic Cause of Long QT Syndrome in a Proband</h2><p>Establishing a specific genetic cause of long QT syndrome (LQTS):</p><ul><li class="half_rhythm"><div>Can aid in discussions of prognosis (which are beyond the scope of this <i>GeneReview</i>) and <a href="#rws.Genetic_Risk_Assessment_and_Evaluati">genetic counseling</a>;</div></li><li class="half_rhythm"><div>Usually involves a medical history, physical examination, family history, and genomic/genetic testing.</div></li></ul><p><b>Clinical</b>
|
|
<b>history.</b> Clinical history in individuals with syncope or a cardiac arrest can reveal specific triggers for the cardiac event that can be gene specific. On rare occasions LQTS is accompanied by gene-specific extracardiac features.</p><p><b>Physical examination.</b> The great majority of individuals with LQTS do not have associated physical features. On rare occasions, LQTS is accompanied by gene-specific extracardiac features. Individuals with EKG characteristics suggestive of a specific LQTS-associated syndrome (e.g., EKG with T-U patterns characteristic of Andersen-Tawil syndrome) can be assessed for physical features of that syndrome.</p><p><b>Family history.</b> A three-generation family history should be taken, with attention to relatives with manifestations of LQTS – including syncope, aborted cardiac arrest, or sudden death in a child or (young) adult – and documentation of relevant findings through direct examination or review of medical records, including results of molecular genetic testing and EKG recordings. Specific focus should also be on triggers of events in relatives, as well as epilepsy (LQTS-associated syncopes may have been attributed to epilepsy). In such instances, review of medical records should include EEG recordings, accompanied by an EKG, which can show QTc prolongation in affected family members.</p><p><b>EKG evaluation.</b> The corrected QT (QTc) values on resting EKG and ST-T wave morphology can suggest a specific genetic cause of LQTS (see <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_phenotype_correla/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromephenotypecorrela">Table 2</a>). Additional tests can be helpful to unmask QTc prolongation in individuals with borderline QTc values on resting EKG [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>]:</p><ul><li class="half_rhythm"><div><b>Exercise EKG,</b> which commonly shows failure of the QTc to shorten normally and even prolongation of the QTc interval [<a class="bibr" href="#rws.REF.jervell.1957.59" rid="rws.REF.jervell.1957.59">Jervell & Lange-Nielsen 1957</a>, <a class="bibr" href="#rws.REF.vincent.1991.498" rid="rws.REF.vincent.1991.498">Vincent et al 1991</a>, <a class="bibr" href="#rws.REF.swan.1998.508" rid="rws.REF.swan.1998.508">Swan et al 1998</a>, <a class="bibr" href="#rws.REF.horner.2011.1698" rid="rws.REF.horner.2011.1698">Horner et al 2011</a>, <a class="bibr" href="#rws.REF.sy.2011.2187" rid="rws.REF.sy.2011.2187">Sy et al 2011</a>]. Many individuals develop characteristic T wave abnormalities [<a class="bibr" href="#rws.REF.zhang.2000.2849" rid="rws.REF.zhang.2000.2849">Zhang et al 2000</a>]. The U wave should not be included in the QT assessment [<a class="bibr" href="#rws.REF.bains.2023.477" rid="rws.REF.bains.2023.477">Bains et al 2023</a>].</div></li><li class="half_rhythm"><div><b>QTc interval measurement</b> during change from supine to standing position [<a class="bibr" href="#rws.REF.viskin.2010.1955" rid="rws.REF.viskin.2010.1955">Viskin et al 2010</a>, <a class="bibr" href="#rws.REF.zeppenfeld.2022.3997" rid="rws.REF.zeppenfeld.2022.3997">Zeppenfeld et al 2022</a>]</div></li><li class="half_rhythm"><div><b>Intravenous pharmacologic provocation</b>
|
|
<b>testing</b> (e.g., with epinephrine), which may demonstrate inappropriate prolongation of the QTc interval [<a class="bibr" href="#rws.REF.ackerman.2002.413" rid="rws.REF.ackerman.2002.413">Ackerman et al 2002</a>]. However, it is not recommended to do this as routine diagnostic testing, as reproducibility is modest [<a class="bibr" href="#rws.REF.churet.2019.896" rid="rws.REF.churet.2019.896">Churet et al 2019</a>, <a class="bibr" href="#rws.REF.zeppenfeld.2022.3997" rid="rws.REF.zeppenfeld.2022.3997">Zeppenfeld et al 2022</a>]. With the small risk of induction of arrhythmia, such provocative testing is best performed in laboratories experienced in arrhythmia induction and control [<a class="bibr" href="#rws.REF.shimizu.2004.276" rid="rws.REF.shimizu.2004.276">Shimizu et al 2004</a>, <a class="bibr" href="#rws.REF.vyas.2006.1385" rid="rws.REF.vyas.2006.1385">Vyas et al 2006</a>].</div></li></ul><p><b>Molecular genetic testing</b> approaches can include a combination of gene-targeted testing (multigene panel) and comprehensive genomic testing (exome sequencing, genome sequencing). Single-gene testing is currently uncommon in LQTS and requires the clinician to hypothesize which gene(s) are likely involved, whereas genomic testing with analysis of a multigene panel does not. For an introduction to multigene panels click <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels_FAQs">here</a>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A LQTS multigene panel</b> that includes the genes listed in <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromegeneticcauses">Table 4</a> is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.</div><div class="half_rhythm">Depending on the sequencing method used and copy number variant detection tools, exon or whole-gene deletions/duplications may not be detected. Exon or multiexon deletions or duplications in <i>KCNH2 or KCNQ1</i> have been identified in approximately 3% of individuals with LQTS [<a class="bibr" href="#rws.REF.barc.2011.40" rid="rws.REF.barc.2011.40">Barc et al 2011</a>]. More rarely, a homozygous deletion of exon 2 in <i>TRDN</i> was described in an individual with QTc prolongation (490 ms), although this individual also had a variant of uncertain significance in <i>RYR2</i> that was inherited from an unaffected father [<a class="bibr" href="#rws.REF.ocallaghan.2018.514" rid="rws.REF.ocallaghan.2018.514">O'Callaghan et al 2018</a>].</div><div class="half_rhythm">Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Single-gene</b>
|
|
<b>testing.</b> Molecular genetic testing based on the individual's phenotype (T wave pattern and triggers of syncope), which has been shown to predict the genotype [<a class="bibr" href="#rws.REF.zhang.2000.2849" rid="rws.REF.zhang.2000.2849">Zhang et al 2000</a>, <a class="bibr" href="#rws.REF.van_langen.2003.141" rid="rws.REF.van_langen.2003.141">Van Langen et al 2003</a>] (see <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_phenotype_correla/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromephenotypecorrela">Table 2</a>), can be performed if a multigene panel is not available or does not contain a specific gene of suspicion.</div></li></ul></div><div id="rws.Management"><h2 id="_rws_Management_">5. Management</h2><div id="rws.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with long QT syndrome (LQTS), the main focus in the management of individuals with LQTS is to identify the subset of individuals at high risk for cardiac events. For this risk stratification the following evaluations are recommended if not performed as part of the evaluation that led to the diagnosis:</p><ul><li class="half_rhythm"><div><b>EKG evaluation.</b> Individuals with a QTc interval >500 ms are at higher risk for a cardiac event; individuals with QTc interval >600 ms are at extremely high risk [<a class="bibr" href="#rws.REF.priori.2003.1866" rid="rws.REF.priori.2003.1866">Priori et al 2003</a>, <a class="bibr" href="#rws.REF.goldenberg.2008.629" rid="rws.REF.goldenberg.2008.629">Goldenberg et al 2008</a>]. Overt T wave alternans, especially when present despite proper beta-blocker therapy, is also associated with a higher risk for cardiac events [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>]. Individuals with a pathogenic variant who have a normal QTc interval are at low risk [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>].</div></li><li class="half_rhythm"><div><b>Medical history.</b> Individuals with syncope or cardiac arrest in the first year of life [<a class="bibr" href="#rws.REF.schwartz.2009.113" rid="rws.REF.schwartz.2009.113">Schwartz et al 2009</a>, <a class="bibr" href="#rws.REF.spazzolini.2009.832" rid="rws.REF.spazzolini.2009.832">Spazzolini et al 2009</a>] or younger than age seven years [<a class="bibr" href="#rws.REF.priori.2004.1341" rid="rws.REF.priori.2004.1341">Priori et al 2004</a>] are at higher risk for an event. These individuals may not be fully protected by pharmacologic treatment. Individuals with arrhythmic events while on proper pharmacologic treatment are also at higher risk [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>]. Asymptomatic individuals with pathogenic variants or individuals with prolonged QT intervals who have been asymptomatic at a young age (age <40 years) are at low risk for events later in life, although females remain at risk after age 40 years [<a class="bibr" href="#rws.REF.locati.1998.2237" rid="rws.REF.locati.1998.2237">Locati et al 1998</a>].</div></li><li class="half_rhythm"><div>To aid in risk stratification, an <b>online calculator</b> named 1-2-3-LQTS-Risk was validated for clinical use [<a class="bibr" href="#rws.REF.mazzanti.2022.614" rid="rws.REF.mazzanti.2022.614">Mazzanti et al 2022</a>], predicting the risk of life-threatening cardiac events in five-year intervals. The prediction accounts for age, sex, QTc interval, history of syncope, and genotype (limited to the three most common genetic causes of LQTS). Further improvement of risk prediction using machine learning and functional imaging has been proposed [<a class="bibr" href="#rws.REF.marathe.2022.697" rid="rws.REF.marathe.2022.697">Marathe et al 2022</a>].</div></li></ul><p>Consultation with a clinical geneticist, certified genetic counselor, certified genetic nurse, or genetics advanced practice provider (nurse practitioner or physician assistant) is recommended to inform affected individuals and their families about the nature, mode of inheritance, and implications of LQTS in order to facilitate medical and personal decision making.</p></div><div id="rws.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="rws.Targeted_Therapy"><h4>Targeted Therapy</h4><p>
|
|
<i>In GeneReviews, a targeted therapy is one that addresses the specific underlying mechanism of disease causation (regardless of whether the therapy is significantly efficacious for one or more manifestation of the genetic condition); would otherwise not be considered without knowledge of the underlying genetic cause of the condition; or could lead to a cure</i>. —ED</p><div id="rws.Asymptomatic_Individuals"><h5>
|
|
<b>Asymptomatic Individuals</b>
|
|
</h5><p><b>Beta-blockers</b> are clinically indicated in all asymptomatic individuals, including those who have a pathogenic variant on molecular genetic testing with a normal QTc interval [<a class="bibr" href="#rws.REF.priori.2004.1341" rid="rws.REF.priori.2004.1341">Priori et al 2004</a>, <a class="bibr" href="#rws.REF.schwartz.2009.113" rid="rws.REF.schwartz.2009.113">Schwartz et al 2009</a>]. Males who have a pathogenic variant and who have been asymptomatic before age 40 years are at low risk for cardiac events. In these individuals the necessity of beta-blockers can be discussed [<a class="bibr" href="#rws.REF.locati.1998.2237" rid="rws.REF.locati.1998.2237">Locati et al 1998</a>].</p><p><b>Implantable cardioverter-defibrillator (ICD).</b> In general, an ICD is <b>not</b> indicated for asymptomatic individuals with LQTS who have not tried beta-blocker therapy. Prophylactic placement of an ICD can be considered for asymptomatic individuals suspected to be at very high risk, such as asymptomatic individuals with two or more pathogenic variants (in genes associated with autosomal dominant LQTS) on molecular genetic testing [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>]. LQTS-related sudden death in a close relative is not an indication for an ICD in an asymptomatic individual [<a class="bibr" href="#rws.REF.kaufman.2008.831" rid="rws.REF.kaufman.2008.831">Kaufman et al 2008</a>].</p></div><div id="rws.Symptomatic_Individuals"><h5>
|
|
<b>Symptomatic Individuals</b>
|
|
</h5><p>All symptomatic persons should be treated [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>]. Complete cessation of symptoms is the goal. Management is focused on the prevention of syncope, cardiac arrest, and sudden death.</p><p><b>Beta-blockers</b> are the mainstay of therapy for LQTS, including asymptomatic individuals with prolonged QT intervals and individuals who have a pathogenic variant on molecular genetic testing with a normal QTc interval [<a class="bibr" href="#rws.REF.priori.2004.1341" rid="rws.REF.priori.2004.1341">Priori et al 2004</a>, <a class="bibr" href="#rws.REF.schwartz.2009.113" rid="rws.REF.schwartz.2009.113">Schwartz et al 2009</a>]. Some individuals have symptoms despite the use of beta-blockers [<a class="bibr" href="#rws.REF.moss.2000.616" rid="rws.REF.moss.2000.616">Moss et al 2000</a>]. However, a majority of cardiac events that occur in individuals with <i>KCNQ1</i>-related LQTS reported to be treated with beta-blockers are not caused by failure of the medication but failure to take the medication (non-adherence) and/or the administration of QT-prolonging drugs [<a class="bibr" href="#rws.REF.vincent.2009.215" rid="rws.REF.vincent.2009.215">Vincent et al 2009</a>]. It is therefore important to:</p><ul><li class="half_rhythm"><div>Avoid inadequate beta-blocker dosing by regular adjustments in growing children, with evaluation of the efficacy of dose by assessment of the exercise EKG or ambulatory EKG;</div></li><li class="half_rhythm"><div>Administer beta-blockers daily, and have strategies in place in case of missed doses;</div></li><li class="half_rhythm"><div>Use long-acting agents (e.g., nadolol) to increase adherence and avoid use of short-acting metoprolol [<a class="bibr" href="#rws.REF.chockalingam.2012.2092" rid="rws.REF.chockalingam.2012.2092">Chockalingam et al 2012</a>];</div></li><li class="half_rhythm"><div>Administer QT-prolonging drugs (see <a href="#rws.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>) to individuals with LQTS <b>ONLY</b> after careful consideration of risk versus benefit by the individual(s) and physician(s).</div></li></ul><p><b>ICD</b> is recommended in individuals with LQTS resuscitated from a cardiac arrest because of the high recurrence risk even when on beta-blocker therapy, although children with <i>KCNQ1</i>-related LQTS with an arrest while not receiving beta-blockers can be treated with beta-blockers or with left cardiac sympathetic denervation [<a class="bibr" href="#rws.REF.alexander.2004.72" rid="rws.REF.alexander.2004.72">Alexander et al 2004</a>, <a class="bibr" href="#rws.REF.vincent.2009.215" rid="rws.REF.vincent.2009.215">Vincent et al 2009</a>, <a class="bibr" href="#rws.REF.jons.2010.783" rid="rws.REF.jons.2010.783">Jons et al 2010</a>]. An ICD can be useful for an individual with beta-blocker-resistant syncopes, ventricular arrhythmias, or a contraindication for beta-blocker therapy (e.g., severe asthma) [<a class="bibr" href="#rws.REF.zareba.2003.337" rid="rws.REF.zareba.2003.337">Zareba et al 2003</a>, <a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>, <a class="bibr" href="#rws.REF.zeppenfeld.2022.3997" rid="rws.REF.zeppenfeld.2022.3997">Zeppenfeld et al 2022</a>].</p><p><b>Left cardiac sympathetic denervation (LCSD)</b> is recommended for high-risk individuals with LQTS in whom ICD therapy is refused or contraindicated and/or in whom beta-blockers are either not effective, not tolerated, not accepted, or contraindicated [<a class="bibr" href="#rws.REF.schwartz.2004.1826" rid="rws.REF.schwartz.2004.1826">Schwartz et al 2004</a>, <a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>, <a class="bibr" href="#rws.REF.zeppenfeld.2022.3997" rid="rws.REF.zeppenfeld.2022.3997">Zeppenfeld et al 2022</a>]. LCSD can be useful in individuals who experience events while on therapy with beta-blockers or ICD [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>].</p><p><b>Sodium channel blockers</b> (e.g., mexiletine) can be useful as additional pharmacologic therapy for individuals with selected pathogenic variants in <i>SCN5A</i> and a QTc interval >500 ms in whom sodium channel blockers are shown to shorten the QTc interval by >40 ms [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>, <a class="bibr" href="#rws.REF.zeppenfeld.2022.3997" rid="rws.REF.zeppenfeld.2022.3997">Zeppenfeld et al 2022</a>].</p><p>Note: Most affected individuals live normal lives. Education of affected adults and the parents of affected children, especially about beta-blocker adherence, is an important aspect of management.</p></div></div><div id="rws.Supportive_Care"><h4>Supportive Care</h4><p>Assess for asthma, orthostatic hypotension, depression, and diabetes mellitus, because these disorders may be exacerbated by treatment with beta-blockers.</p><p>Electrolyte imbalances may lengthen the QTc interval; identification and correction of electrolyte abnormalities is important. These imbalances can occur as a result of diarrhea, vomiting, metabolic conditions, and unbalanced diets used for weight loss.</p><p>Although the incidence of arrhythmias during elective interventions such as surgery, endoscopies, childbirth, or dental work is low, it is prudent to monitor the EKG during such interventions and to alert the appropriate medical personnel in case intervention is needed.</p><p>Lifestyle modifications are advised based on genotype (see <a href="#rws.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</p></div></div><div id="rws.Surveillance"><h3>Surveillance</h3><p>Beta-blocker dose should be regularly assessed for efficacy and adverse effects; doses should be altered as needed. Dose adjustment including efficacy testing is especially important in growing children.</p><p>Individuals with an ICD should have regular, periodic evaluations of the ICD for inappropriate shocks and pocket or lead complications.</p></div><div id="rws.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Drugs that cause further prolongation of the QT interval or provoke torsade de pointes should be avoided for all individuals with LQTS. See <a href="https://www.crediblemeds.org/index.php/login/dlcheck" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">CredibleMeds<sup>®</sup></a> (free registration required) for a complete and updated list.</p><p>Epinephrine given as part of local anesthetics can trigger arrhythmias and is best avoided.</p><p>Lifestyle modifications are advised based on genotype:</p><ul><li class="half_rhythm"><div>Individuals with <i>KCNQ1</i>-related LQTS should avoid strenuous exercise, especially swimming without supervision.</div></li><li class="half_rhythm"><div>Individuals with <i>KCNH2</i>-related LQTS should avoid exposure to loud noises such as alarm clocks and phone ringing.</div></li><li class="half_rhythm"><div>Individuals at high risk for cardiac events or with exercise-induced symptoms (as in <i>KCNH2</i>- and <i>KCNQ1</i>-related LQTS) should avoid competitive sports [<a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>]. For some individuals, participation in competitive sports may be safe. It is therefore recommended that all individuals with LQTS who wish to engage in competitive sports have their risk evaluated by a clinical expert [<a class="bibr" href="#rws.REF.johnson.2012.764" rid="rws.REF.johnson.2012.764">Johnson & Ackerman 2012</a>, <a class="bibr" href="#rws.REF.priori.2013.1932" rid="rws.REF.priori.2013.1932">Priori et al 2013</a>].</div></li></ul></div><div id="rws.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The postpartum period is associated with increased risk for a cardiac event, especially in individuals with <i>KCNH2</i>-related LQTS. Beta-blocker treatment was associated with a reduction of events in the nine months after delivery [<a class="bibr" href="#rws.REF.seth.2007.1092" rid="rws.REF.seth.2007.1092">Seth et al 2007</a>]. Recommendations for optimal care during and after pregnancy, including suitability of anti-arrhythmic drugs and surveillance measures, can be found in <a class="bibr" href="#rws.REF.roston.2020.341" rid="rws.REF.roston.2020.341">Roston et al [2020]</a>.</p><p>See <a href="https://www.mothertobaby.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="rws.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A current study is evaluating the drug ranolazine in individuals with <i>SCN5A-</i>related LQTS [<a class="bibr" href="#rws.REF.cano.2020.580481" rid="rws.REF.cano.2020.580481">Cano et al 2020</a>].</p><p>For individuals with <i>KCNH2-</i>related LQTS due to a protein trafficking defect, combined treatment with lumacraftor and ivacraftor is under investigation [<a class="bibr" href="#rws.REF.schwartz.2019.1832" rid="rws.REF.schwartz.2019.1832">Schwartz et al 2019</a>].</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinicalTrials.gov</a> in the US and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="rws.Genetic_Risk_Assessment_and_Evaluati"><h2 id="_rws_Genetic_Risk_Assessment_and_Evaluati_">6. Genetic Risk Assessment and Evaluations of At-Risk Relatives for Early Detection and Treatment of Long QT Syndrome</h2><p>
|
|
<i>Genetic counseling is the process of providing individuals and families with
|
|
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
|
|
make informed medical and personal decisions. The following section deals with genetic
|
|
risk assessment and the use of family history and genetic testing to clarify genetic
|
|
status for family members; it is not meant to address all personal, cultural, or
|
|
ethical issues that may arise or to substitute for consultation with a genetics
|
|
professional</i>. —ED.</p><div id="rws.Genetic_Risk_Assessment"><h3>Genetic Risk Assessment</h3><p>Long QT syndrome (LQTS) without extracardiac features is typically inherited in an autosomal dominant manner. <a href="/books/n/gene/timothy/?report=reader">Timothy syndrome</a> (caused by a heterozygous pathogenic variant in <i>CACNA1C</i>) and <a href="/books/n/gene/acpp/?report=reader">Andersen-Tawil syndrome</a> (caused by heterozygous pathogenic variant in <i>KCNJ2</i>), types of LQTS that are associated with a phenotype extending beyond cardiac arrhythmia, are also inherited in an autosomal dominant manner. <a href="/books/n/gene/jln/?report=reader">Jervell and Lange-Nielsen syndrome</a>, a severe form of autosomal recessive LQTS with a high event risk at early age and deafness, is caused by biallelic pathogenic variants in <i>KCNQ1</i> or <i>KCNE1</i>. Biallelic pathogenic variants in <i>TRDN</i> cause another very rare and severe form of autosomal recessive LQTS-catecholaminergic polymorphic ventricular tachycardia (CPVT) overlap syndrome (see <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_mode_of_inheritan/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromemodeofinheritan">Table 5</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figrwsTlongqtsyndromemodeofinheritan"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_mode_of_inheritan/?report=objectonly" target="object" title="Table 5. " class="img_link icnblk_img" rid-ob="figobrwsTlongqtsyndromemodeofinheritan"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="rws.T.long_qt_syndrome_mode_of_inheritan"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_mode_of_inheritan/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromemodeofinheritan">Table 5. </a></h4><p class="float-caption no_bottom_margin">Long QT Syndrome: Mode of Inheritance </p></div></div><p>LQTS associated with biallelic pathogenic variants (in genes associated with autosomal dominant LQTS) or heterozygosity for pathogenic variants in two different genes (i.e., digenic pathogenic variants) has also been reported (see <a href="#rws.Biallelic_Pathogenic_Variants__Digen">Biallelic Pathogenic Variants / Digenic Inheritance</a>).</p></div><div id="rws.Risk_to_Family_Members_Autosomal_Dom"><h3>Risk to Family Members (Autosomal Dominant Inheritance)</h3><p>A basic view of autosomal dominant LQTS genetic risk assessment is presented in this section; issues that may be specific to a given family or genetic cause of LQTS are not comprehensively addressed. If a proband has a specific syndrome (e.g., <a href="/books/n/gene/timothy/?report=reader">Timothy syndrome</a> or <a href="/books/n/gene/acpp/?report=reader">Andersen-Tawil syndrome</a>), counseling for that condition is indicated. Genetic risk assessment in families with LQTS with extracardiac features is not discussed further in this section.</p><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>The majority of individuals diagnosed with LQTS inherited a pathogenic variant from a parent. Due to reduced penetrance and variable expressivity, a parent who is heterozygous for an LQTS-related pathogenic variant may or may not have LQTS-related EKG changes and symptoms.</div></li><li class="half_rhythm"><div>A proband with LQTS may have the disorder as the result of a <i>de novo</i> pathogenic variant. The proportion of individuals with LQTS caused by a <i>de novo</i> pathogenic variant is small.</div></li><li class="half_rhythm"><div>If a molecular diagnosis has been established in the proband, molecular genetic testing is recommended for the parents of the proband to evaluate their genetic status, inform recurrence risk assessment, and facilitate the use of morbidity- and mortality-reducing interventions for parents found to be heterozygous for an LQTS-related pathogenic variant.</div></li><li class="half_rhythm"><div>If the pathogenic variant identified in the proband is not identified in either parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div>The proband has a <i>de novo</i> pathogenic variant.</div></li><li class="half_rhythm"><div>The proband inherited a pathogenic variant from a parent with germline (or somatic and germline) mosaicism (the incidence of germline mosaicism is very low: 0.1% [<a class="bibr" href="#rws.REF.acunahidalgo.2015.67" rid="rws.REF.acunahidalgo.2015.67">Acuna-Hidalgo et al 2015</a>]). Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a pathogenic variant that is present in the germ (gonadal) cells only.</div></li></ul></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with LQTS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or reduced penetrance. Therefore, an apparently negative family history does not exclude the possibility of an inherited pathogenic variant and molecular genetic testing is indicated.</div></li></ul><p>Note: Biallelic and digenic pathogenic variants have been described. If an individual with LQTS has biallelic or digenic pathogenic variants, the possibility that both parents have pathogenic variants should be considered.</p><p><b>Sibs of a proband.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the proband is heterozygous for the pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%. Because LQTS exhibits reduced penetrance, sibs who inherit a pathogenic variant may or may not have symptomatic LQTS. Considerable phenotypic variability within families has also been reported [<a class="bibr" href="#rws.REF.giudicessi.2018.619" rid="rws.REF.giudicessi.2018.619">Giudicessi et al 2018</a>].</div></li><li class="half_rhythm"><div>If the proband has a known LQTS-related pathogenic variant that cannot be detected in the leukocyte DNA of either parent; the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental germline mosaicism [<a class="bibr" href="#rws.REF.priest.2016.11555" rid="rws.REF.priest.2016.11555">Priest et al 2016</a>].</div></li><li class="half_rhythm"><div>If the parents do not have signs of LQTS on cardiac evaluation but their genetic status is unknown, the risk to sibs of inheriting an LQTS-related pathogenic variant is estimated to be 50% because a heterozygous parent may be clinically unaffected due to reduced penetrance of LQTS-related EKG changes and symptoms. The likelihood that the proband has LQTS as the result of a pathogenic variant inherited from a heterozygous asymptomatic parent is far greater than the likelihood that the proband has LQTS as the result of a <i>de novo</i> pathogenic variant.</div></li></ul><p><b>Offspring of a proband.</b> Each child of an individual with LQTS has a 50% chance of inheriting the pathogenic variant.</p><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the proband's parents: if a parent is clinically affected and/or has a pathogenic variant, the parent's family members are at risk.</p></div><div id="rws.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p><b>Specific risk issues.</b> With the reduced penetrance of symptoms in individuals with LQTS, careful EKG evaluation including exercise EKG is often necessary to identify affected family members accurately. The absence of a family history of sudden death is common and does not negate the diagnosis or preclude the possibility of sudden death in relatives.</p><p><b>Predictive genetic testing in family members of a proband with a molecular diagnosis of LQTS.</b> If the LQTS-related pathogenic variant(s) has been identified in a proband, it is appropriate to clarify the genetic status of apparently asymptomatic relatives so that individuals found to be heterozygous for an LQTS-related pathogenic variant can benefit as early as possible from prompt initiation of <a href="#rws.Targeted_Therapy">targeted therapy</a>, <a href="#rws.Surveillance">surveillance</a>, and awareness of <a href="#rws.AgentsCircumstances_to_Avoid">agents and circumstances to avoid</a> (e.g., drugs that cause further prolongation of the QT interval and gene-specific cardiac event triggers). Predictive genetic testing is recommended for all at-risk family members of all ages from birth onward and especially for individuals age <18 years because the risk for cardiac events is greatest in childhood [<a class="bibr" href="#rws.REF.wilde.2022.332" rid="rws.REF.wilde.2022.332">Wilde et al 2022</a>].</p><p>Predictive genetic testing can be used to identify relatives who are heterozygous for a familial LQTS-related pathogenic variant and at risk for LQTS-related manifestations but cannot be used to predict disease course (i.e., whether LQTS-related EKG changes and symptoms will occur and, if so, the age of onset and severity).</p><p><b>Evaluation of family members of a proband with a clinical diagnosis of LQTS.</b> If the LQTS-related pathogenic variant in the proband is not known (as is the case in ≤25% of individuals with LQTS who undergo molecular genetic testing for known LQTS-related genes [<a class="bibr" href="#rws.REF.ingles.2020.440" rid="rws.REF.ingles.2020.440">Ingles & Semsarian 2020</a>]) and the LQTS does not seem to be acquired, first-degree relatives should still be considered to be at risk. These relatives should undergo QTc analysis on resting EKG and, in those with normal QTc on resting EKG, QTc analysis on exercise EKG (the diagnostic accuracy by QTc analysis is considerably improved by evaluation of the exercise EKG in addition to the resting EKG, using the QTc measurements listed in <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_scoring_system_fo/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromescoringsystemfo">Table 1</a>). To date, there are no clear recommendations on when to repeat the EKG in individuals with normal findings.</p><p>Note: Because LQTS exhibits reduced penetrance for EKG changes and symptoms, the absence of LQTS-related findings on EKG evaluation cannot be used to assess genetic status (i.e., an individual who is heterozygous for an LQTS-related pathogenic variant may have a normal QTc on baseline EKG).</p><p><b>DNA banking.</b> Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see <a class="bibr" href="#rws.REF.huang.2022.389" rid="rws.REF.huang.2022.389">Huang et al [2022]</a>.</p></div></div><div id="rws.Resources"><h2 id="_rws_Resources_">Resources</h2><p>
|
|
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
|
|
support organizations and/or registries for the benefit of individuals with this disorder
|
|
and their families. GeneReviews is not responsible for the information provided by other
|
|
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/?report=reader">here</a>.</i></p>
|
|
<ul><li class="half_rhythm"><div>
|
|
<b>National Heart, Lung, and Blood Institute (NHLBI)</b>
|
|
</div><div>
|
|
<a href="https://www.nhlbi.nih.gov/health/long-qt-syndrome" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Long QT Syndrome</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation</b>
|
|
</div><div>Canada</div><div><b>Email:</b> info@sads.ca</div><div>
|
|
<a href="https://www.sads.ca/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">sads.ca</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Sudden Arrhythmia Death Syndromes (SADS) Foundation</b>
|
|
</div><div><b>Phone:</b> 801-948-0654; 801-272-3023</div><div><b>Email:</b> sads@sads.org</div><div>
|
|
<a href="http://www.sads.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">sads.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>International Long QT Syndrome Registry</b>
|
|
</div><div>Heart Research Follow-Up Program</div><div><b>Phone:</b> 585-276-0016</div><div><b>Email:</b> heartajm@heart.rochester.edu</div><div>
|
|
<a href="https://rarediseases.org/organizations/international-long-qt-syndrome-registry/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">rarediseases.org/organizations/international-long-qt-syndrome-registry</a>
|
|
</div></li></ul>
|
|
</div><div id="rws.Chapter_Notes"><h2 id="_rws_Chapter_Notes_">Chapter Notes</h2><div id="rws.Author_History"><h3>Author History</h3><p>Mariëlle Alders, PhD; Amsterdam University Medical Center (2012-2024)<br />Hennie Bikker, PhD (2018-present)<br />Imke Christiaans, PhD, MD (2015-present)<br />Alexander J Groffen, PhD (2024-present)<br />Marcel MAM Mannens, PhD; University of Amsterdam (2012-2015)<br />G Michael Vincent, MD; University of Utah School of Medicine (2003-2012)</p></div><div id="rws.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 March 2024 (sw) Comprehensive update posted live; scope changed to overview</div></li><li class="half_rhythm"><div>8 February 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 June 2015 (me) Comprehensive update posted live (title change)</div></li><li class="half_rhythm"><div>31 May 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 May 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 July 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 February 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>25 October 2002 (gmv) Original submission</div></li></ul></div></div><div id="rws.References"><h2 id="_rws_References_">References</h2><div id="rws.Published_Guidelines__Consensus_Stat"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div>American College of Cardiology/American Heart Association Task Force, and the European Society of Cardiology/Committee for Practice Guidelines. Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Available <a href="https://circ.ahajournals.org/content/114/10/1088.full.pdf+html" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">online</a>. 2006. Accessed 2-27-24.</div></li><li class="half_rhythm"><div>Fellmann F, van El CG, Charron P, Michaud K, Howard HC, Boers SN, Clarke AJ, Duguet AM, Forzano F, Kauferstein S, Kayserili H, Lucassen A, Mendes A, Patch C, Radojkovic D, Rial-Sebbag E, Sheppard MN, Tasse AM, Temel SG, Sajantila A, Basso C, Wilde AAM, Cornel MC, on behalf of European Society of Human Genetics ECoLMESoCwgom, pericardial diseases ERNfrlp, complex diseases of the heart AfECP. European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. Eur J Hum Genet. 2019;27:1763-73.</div></li><li class="half_rhythm"><div>Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932-63.</div></li><li class="half_rhythm"><div>Stiles MK, Wilde AAM, Abrams DJ, Ackerman MJ, Albert CM, Behr ER, Chugh SS, Cornel MC, Gardner K, Ingles J, James CA, Juang JJ, Kaab S, Kaufman ES, Krahn AD, Lubitz SA, MacLeod H, Morillo CA, Nademanee K, Probst V, Saarel EV, Sacilotto L, Semsarian C, Sheppard MN, Shimizu W, Skinner JR, Tfelt-Hansen J, Wang DW. 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. J Arrhythm. 2021;37:481-534.</div></li><li class="half_rhythm"><div>Vincent GM. Role of DNA testing for diagnosis, management, and genetic screening in long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1729812/pdf/v086p00012.pdf" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">online</a>. 2001. Accessed 2-27-24.</div></li><li class="half_rhythm"><div>Wilde AAM, Semsarian C, Marquez MF, Sepehri Shamloo A, Ackerman MJ, Ashley EA, Sternick EB, Barajas-Martinez H, Behr ER, Bezzina CR, Breckpot J, Charron P, Chockalingam P, Crotti L, Gollob MH, Lubitz S, Makita N, Ohno S, Ortiz-Genga M, Sacilotto L, Schulze-Bahr E, Shimizu W, Sotoodehnia N, Tadros R, Ware JS, Winlaw DS, Kaufman ES, Group ESCSD. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022;24:1307-67.</div></li><li class="half_rhythm"><div>Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M, Group ESCSD. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997-4126.</div></li></ul></div><div id="rws.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.ackerman.2002.413">Ackerman
|
|
MJ, Khositseth
|
|
A, Tester
|
|
DJ, Hejlik
|
|
JB, Shen
|
|
WK, Porter
|
|
CB. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome.
|
|
Mayo Clin Proc.
|
|
2002;77:413–21.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12004990" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12004990</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.ackerman.2001.2264">Ackerman
|
|
MJ, Siu
|
|
BL, Sturner
|
|
WQ, Tester
|
|
DJ, Valdivia
|
|
CR, Makielski
|
|
JC, Towbin
|
|
JA. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome.
|
|
JAMA. 2001;286:2264–9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11710892" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11710892</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.acunahidalgo.2015.67">Acuna-Hidalgo
|
|
R, Bo
|
|
T, Kwint
|
|
MP, van de Vorst
|
|
M, Pinelli
|
|
M, Veltman
|
|
JA, Hoischen
|
|
A, Vissers
|
|
LE, Gilissen
|
|
C. Post-zygotic point mutations are an underrecognized source of de novo genomic variation.
|
|
Am J Hum Genet.
|
|
2015;97:67-74.
|
|
[<a href="/pmc/articles/PMC4571017/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4571017</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26054435" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26054435</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.adler.2020.418">Adler
|
|
A, Novelli
|
|
V, Amin
|
|
AS, Abiusi
|
|
E, Care
|
|
M, Nannenberg
|
|
EA, Feilotter
|
|
H, Amenta
|
|
S, Mazza
|
|
D, Bikker
|
|
H, Sturm
|
|
AC, Garcia
|
|
J, Ackerman
|
|
MJ, Hershberger
|
|
RE, Perez
|
|
MV, Zareba
|
|
W, Ware
|
|
JS, Wilde
|
|
AAM, Gollob
|
|
MH. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome.
|
|
Circulation.
|
|
2020;141:418-28.
|
|
[<a href="/pmc/articles/PMC7017940/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7017940</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31983240" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31983240</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.alexander.2004.72">Alexander
|
|
ME, Cecchin
|
|
F, Walsh
|
|
EP, Triedman
|
|
JK, Bevilacqua
|
|
LM, Berul
|
|
CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics.
|
|
J Cardiovasc Electrophysiol.
|
|
2004;15:72–6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15028076" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15028076</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.altmann.2015.2051">Altmann
|
|
HM, Tester
|
|
DJ, Will
|
|
ML, Middha
|
|
S, Evans
|
|
JM, Eckloff
|
|
BW, Ackerman
|
|
MJ. Homozygous/compound heterozygous triadin mutations associated with autosomal-recessive long-QT syndrome and pediatric sudden cardiac arrest: elucidation of the triadin knockout syndrome.
|
|
Circulation.
|
|
2015;131:2051-60.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25922419" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25922419</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.arnestad.2007.361">Arnestad
|
|
M, Crotti
|
|
L, Rognum
|
|
TO, Insolia
|
|
R, Pedrazzini
|
|
M, Ferrandi
|
|
C, Vege
|
|
A, Wang
|
|
DW, Rhodes
|
|
TE, George
|
|
AL
|
|
Jr, Schwartz
|
|
PJ. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome.
|
|
Circulation.
|
|
2007;115:361–7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17210839" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17210839</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.bains.2023.477">Bains
|
|
S, Neves
|
|
R, Bos
|
|
JM, Giudicessi
|
|
JR, MacIntyre
|
|
C, Ackerman
|
|
MJ. Phenotypes of overdiagnosed long QT syndrome.
|
|
J Am Coll Cardiol.
|
|
2023;81:477-86.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/36725176" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36725176</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.barc.2011.40">Barc
|
|
J, Briec
|
|
F, Schmitt
|
|
S, Kyndt
|
|
F, Le Cunff
|
|
M, Baron
|
|
E, Vieyres
|
|
C, Sacher
|
|
F, Redon
|
|
R, Le Caignec
|
|
C, Le Marec
|
|
H, Probst
|
|
V, Schott
|
|
JJ. Screening for copy number variation in genes associated with the long QT syndrome: clinical relevance.
|
|
J Am Coll Cardiol.
|
|
2011;57:40–7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21185499" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21185499</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.cano.2020.580481">Cano
|
|
J, Zorio
|
|
E, Mazzanti
|
|
A, Arnau
|
|
MA, Trenor
|
|
B, Priori
|
|
SG, Saiz
|
|
J, Romero
|
|
L. Ranolazine as an alternative therapy to flecainide for SCN5A V411M long QT syndrome type 3 patients.
|
|
Front Pharmacol.
|
|
2020;11:580481.
|
|
[<a href="/pmc/articles/PMC7845660/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7845660</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33519442" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33519442</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.chockalingam.2012.2092">Chockalingam
|
|
P, Crotti
|
|
L, Girardengo
|
|
G, Johnson
|
|
JN, Harris
|
|
KM, van der Heijden
|
|
JF, Hauer
|
|
RN, Beckmann
|
|
BM, Spazzolini
|
|
C, Rordorf
|
|
R, Rydberg
|
|
A, Clur
|
|
SA, Fischer
|
|
M, van den Heuvel
|
|
F, Kääb
|
|
S, Blom
|
|
NA, Ackerman
|
|
MJ, Schwartz
|
|
PJ, Wilde
|
|
AA. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol.
|
|
J Am Coll Cardiol.
|
|
2012;60:2092–9.
|
|
[<a href="/pmc/articles/PMC3515779/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3515779</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23083782" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23083782</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.churet.2019.896">Churet
|
|
M, Luttoo
|
|
K, Hocini
|
|
M, Haissaguerre
|
|
M, Sacher
|
|
F, Duchateau
|
|
J. Diagnostic reproducibility of epinephrine drug challenge interpretation in suspected long QT syndrome.
|
|
J Cardiovasc Electrophysiol.
|
|
2019;30:896-901.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30907461" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30907461</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.giudicessi.2013.417">Giudicessi
|
|
JR, Ackerman
|
|
MJ. Genotype- and phenotype-guided management of congenital long QT syndrome.
|
|
Curr Probl Cardiol.
|
|
2013;38:417-55.
|
|
[<a href="/pmc/articles/PMC3940076/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3940076</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24093767" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24093767</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.giudicessi.2018.619">Giudicessi
|
|
JR, Roden
|
|
DM, Wilde
|
|
AAM, Ackerman
|
|
MJ. Classification and reporting of potentially proarrhythmic common genetic variation in long QT syndrome genetic testing.
|
|
Circulation.
|
|
2018;137:619-30.
|
|
[<a href="/pmc/articles/PMC6383807/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6383807</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29431662" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29431662</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.goldenberg.2011.51">Goldenberg
|
|
I, Horr
|
|
S, Moss
|
|
AJ, Lopes
|
|
CM, Barsheshet
|
|
A, McNitt
|
|
S, Zareba
|
|
W, Andrews
|
|
ML, Robinson
|
|
JL, Locati
|
|
EH, Ackerman
|
|
MJ, Benhorin
|
|
J, Kaufman
|
|
ES, Napolitano
|
|
C, Platonov
|
|
PG, Priori
|
|
SG, Qi
|
|
M, Schwartz
|
|
PJ, Shimizu
|
|
W, Towbin
|
|
JA, Vincent
|
|
GM, Wilde
|
|
AA, Zhang
|
|
L. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals.
|
|
J Am Coll Cardiol.
|
|
2011;57:51–9.
|
|
[<a href="/pmc/articles/PMC3332533/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3332533</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21185501" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21185501</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.goldenberg.2008.629">Goldenberg
|
|
I, Zareba
|
|
W, Moss
|
|
AJ. Long QT syndrome.
|
|
Curr Probl Cardiol.
|
|
2008;33:629–94.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18835466" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18835466</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.he.2022.1595">He
|
|
M, Qiu
|
|
J, Wang
|
|
Y, Bai
|
|
Y, Chen
|
|
G.
|
|
Caveolin-3 and arrhythmias: insights into the molecular mechanisms.
|
|
J Clin Med.
|
|
2022;11:1595.
|
|
[<a href="/pmc/articles/PMC8952412/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8952412</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35329921" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35329921</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.horner.2011.1698">Horner
|
|
JM, Horner
|
|
MM., Ackermann
|
|
MJ.
|
|
The diagnostic utility of recovery phase QTc during treadmill exercise stress testing in the evaluation of long QT syndrome.
|
|
Heart Rhythm.
|
|
2011;8:1698–704.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21699858" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21699858</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.huang.2022.389">Huang
|
|
SJ, Amendola
|
|
LM, Sternen
|
|
DL. Variation among DNA banking consent forms: points for clinicians to bank on.
|
|
J Community Genet.
|
|
2022;13:389-97.
|
|
[<a href="/pmc/articles/PMC9314484/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9314484</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35834113" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35834113</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.ingles.2020.440">Ingles
|
|
J, Semsarian
|
|
C. Time to rethink the genetic architecture of long QT syndrome.
|
|
Circulation.
|
|
2020;141:440-3.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32078431" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32078431</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.itoh.2010.1411">Itoh
|
|
H, Shimizu
|
|
W, Hayashi
|
|
K, Yamagata
|
|
K, Sakaguchi
|
|
T, Ohno
|
|
S, Makiyama
|
|
T, Akao
|
|
M, Ai
|
|
T, Noda
|
|
T, Miyazaki
|
|
A, Miyamoto
|
|
Y, Yamagishi
|
|
M, Kamakura
|
|
S, Horie
|
|
M.
|
|
Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study.
|
|
Heart Rhythm.
|
|
2010;7:1411–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20541041" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20541041</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.jervell.1957.59">Jervell
|
|
A, Lange-Nielsen
|
|
F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death.
|
|
Am Heart J.
|
|
1957;54:59–68.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/13435203" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13435203</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.johnson.2012.764">Johnson
|
|
JN, Ackerman
|
|
MJ. Competitive sports participation in athletes with congenital long QT syndrome.
|
|
JAMA. 2012;308:764–5.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22820673" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22820673</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.jons.2010.783">Jons
|
|
C, Moss
|
|
AJ, Goldenberg
|
|
I, Liu
|
|
J, McNitt
|
|
S, Zareba
|
|
W, Qi
|
|
M, Robinson
|
|
JL. Risk of fatal arrhythmic events in long QT syndrome patients after syncope.
|
|
J Am Coll Cardiol.
|
|
2010;55:783–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20170817" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20170817</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.kaufman.2008.831">Kaufman
|
|
ES, McNitt
|
|
S, Moss
|
|
AJ, Zareba
|
|
W, Robinson
|
|
JL, Hall
|
|
WJ, Ackerman
|
|
MJ, Benhorin
|
|
J, Locati
|
|
ET, Napolitano
|
|
C, Priori
|
|
SG, Schwartz
|
|
PJ, Towbin
|
|
JA, Vincent
|
|
GM, Zhang
|
|
L. Risk of death in the long QT syndrome when a sibling has died.
|
|
Heart Rhythm.
|
|
2008;5:831–6.
|
|
[<a href="/pmc/articles/PMC2486317/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2486317</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18534367" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18534367</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.kutyifa.2018.e12537">Kutyifa
|
|
V, Daimee
|
|
UA, McNitt
|
|
S, Polonsky
|
|
B, Lowenstein
|
|
C, Cutter
|
|
K, Lopes
|
|
C, Zareba
|
|
W, Moss
|
|
AJ. Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3).
|
|
Ann Noninvasive Electrocardiol.
|
|
2018;23:e12537.
|
|
[<a href="/pmc/articles/PMC5980697/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5980697</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29504689" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29504689</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.lieve.2015.ii1">Lieve
|
|
KV, Wilde
|
|
AA. Inherited ion channel diseases: a brief review.
|
|
Europace.
|
|
2015;17
|
|
Suppl 2:ii1–ii6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26842110" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26842110</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.locati.1998.2237">Locati
|
|
EH, Zareba
|
|
W, Moss
|
|
AJ, Schwartz
|
|
PJ, Vincent
|
|
GM, Lehmann
|
|
MH, Towbin
|
|
JA, Priori
|
|
SG, Napolitano
|
|
C, Robinson
|
|
JL, Andrews
|
|
M, Timothy
|
|
K, Hall
|
|
WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry.
|
|
Circulation.
|
|
1998;97:2237–44.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9631873" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9631873</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.marathe.2022.697">Marathe
|
|
K, Marwood
|
|
OEG, Ahmad
|
|
M. Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment. Europace.
|
|
2022;24:697-8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/35303093" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35303093</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.mazzanti.2022.614">Mazzanti
|
|
A, Trancuccio
|
|
A, Kukavica
|
|
D, Pagan
|
|
E, Wang
|
|
M, Mohsin
|
|
M, Peterson
|
|
D, Bagnardi
|
|
V, Zareba
|
|
W, Priori
|
|
SG. Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk).
|
|
Europace.
|
|
2022;24:614-9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34505884" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34505884</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.moss.2000.616">Moss
|
|
AJ, Zareba
|
|
W, Hall
|
|
WJ, Schwartz
|
|
PJ, Crampton
|
|
RS, Benhorin
|
|
J, Vincent
|
|
GM, Locati
|
|
EH, Priori
|
|
SG, Napolitano
|
|
C, Medina
|
|
A, Zhang
|
|
L, Robinson
|
|
JL, Timothy
|
|
K, Towbin
|
|
JA, Andrews
|
|
ML. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome.
|
|
Circulation.
|
|
2000;101:616–23.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/10673253" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10673253</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.mullally.2013.378">Mullally
|
|
J, Goldenberg
|
|
I, Moss
|
|
AJ, Lopes
|
|
CM, Ackerman
|
|
MJ, Zareba
|
|
W, McNitt
|
|
S, Robinson
|
|
JL, Benhorin
|
|
J, Kaufman
|
|
ES, Towbin
|
|
JA, Barsheshet
|
|
A. Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations.
|
|
Heart Rhythm.
|
|
2013;10:378-82.
|
|
[<a href="/pmc/articles/PMC3690288/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3690288</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23174487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23174487</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.ocallaghan.2018.514">O'Callaghan
|
|
BM, Hancox
|
|
JC, Stuart
|
|
AG, Armstrong
|
|
C, Williams
|
|
MM, Hills
|
|
A, Pearce
|
|
H, Dent
|
|
CL, Gable
|
|
M, Walsh
|
|
MA. A unique triadin exon deletion causing a null phenotype.
|
|
HeartRhythm Case Rep.
|
|
2018;4:514-8.
|
|
[<a href="/pmc/articles/PMC6241331/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6241331</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30479949" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30479949</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.ormerod.2022.e003589">Ormerod
|
|
JOM, Ormondroyd
|
|
E, Li
|
|
Y, Taylor
|
|
J, Wei
|
|
J, Guo
|
|
W, Wang
|
|
R, Sarton
|
|
CNS, McGuire
|
|
K, Dreau
|
|
HMP, Taylor
|
|
JC, Ginks
|
|
MR, Rajappan
|
|
K, Chen
|
|
SRW, Watkins
|
|
H. Provocation testing and therapeutic response in a newly described channelopathy: RyR2 calcium release deficiency syndrome.
|
|
Circ Genom Precis Med.
|
|
2022;15:e003589.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34949103" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34949103</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.priest.2016.11555">Priest
|
|
JR, Gawad
|
|
C, Kahlig
|
|
KM, Yu
|
|
JK, O'Hara
|
|
T, Boyle
|
|
PM, Rajamani
|
|
S, Clark
|
|
MJ, Garcia
|
|
ST, Ceresnak
|
|
S, Harris
|
|
J, Boyle
|
|
S, Dewey
|
|
FE, Malloy-Walton
|
|
L, Dunn
|
|
K, Grove
|
|
M, Perez
|
|
MV, Neff
|
|
NF, Chen
|
|
R, Maeda
|
|
K, Dubin
|
|
A, Belardinelli
|
|
L, West
|
|
J, Antolik
|
|
C, Macaya
|
|
D, Quertermous
|
|
T, Trayanova
|
|
NA, Quake
|
|
SR, Ashley
|
|
EA. Early somatic mosaicism is a rare cause of long-QT syndrome.
|
|
Proc Natl Acad Sci U S A.
|
|
2016;113:11555–60.
|
|
[<a href="/pmc/articles/PMC5068256/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5068256</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27681629" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27681629</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.priori.2004.1341">Priori
|
|
SG, Napolitano
|
|
C, Schwartz
|
|
PJ, Grillo
|
|
M, Bloise
|
|
R, Ronchetti
|
|
E, Moncalvo
|
|
C, Tulipani
|
|
C, Veia
|
|
A, Bottelli
|
|
G, Nastoli
|
|
J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.
|
|
JAMA. 2004;292:1341–4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15367556" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15367556</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.priori.2003.1866">Priori
|
|
SG, Schwartz
|
|
PJ, Napolitano
|
|
C, Bloise
|
|
R, Ronchetti
|
|
E, Grillo
|
|
M, Vicentini
|
|
A, Spazzolini
|
|
C, Nastoli
|
|
J, Bottelli
|
|
G, Folli
|
|
R, Cappelletti
|
|
D. Risk stratification in the long-QT syndrome.
|
|
N Engl J Med.
|
|
2003;348:1866–74.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12736279" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12736279</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.priori.2013.1932">Priori
|
|
SG, Wilde
|
|
AA, Horie
|
|
M, Cho
|
|
Y, Behr
|
|
ER, Berul
|
|
C, Blom
|
|
N, Brugada
|
|
J, Chiang
|
|
CE, Huikuri
|
|
H, Kannankeril
|
|
P, Krahn
|
|
A, Leenhardt
|
|
A, Moss
|
|
A, Schwartz
|
|
PJ, Shimizu
|
|
W, Tomaselli
|
|
G, Tracy
|
|
C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.
|
|
Heart Rhythm.
|
|
2013;10:1932–63.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24011539" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24011539</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.roston.2020.341">Roston
|
|
TM, van der Werf
|
|
C, Cheung
|
|
CC, Grewal
|
|
J, Davies
|
|
B, Wilde
|
|
AAM, Krahn
|
|
AD. Caring for the pregnant woman with an inherited arrhythmia syndrome.
|
|
Heart Rhythm.
|
|
2020;17:341-8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31400520" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31400520</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.schwartz.2011.2181">Schwartz
|
|
PJ, Crotti
|
|
L. QTc behavior during exercise and genetic testing for the long-QT syndrome.
|
|
Circulation.
|
|
2011;124:2181–4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22083145" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22083145</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.schwartz.2019.1832">Schwartz
|
|
PJ, Gnecchi
|
|
M, Dagradi
|
|
F, Castelletti
|
|
S, Parati
|
|
G, Spazzolini
|
|
C, Sala
|
|
L, Crotti
|
|
L. From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2.
|
|
Eur Heart J.
|
|
2019;40:1832-6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30753398" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30753398</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.schwartz.2004.1826">Schwartz
|
|
PJ, Priori
|
|
SG, Cerrone
|
|
M, Spazzolini
|
|
C, Odero
|
|
A, Napolitano
|
|
C, Bloise
|
|
R, De Ferrari
|
|
GM, Klersy
|
|
C, Moss
|
|
AJ, Zareba
|
|
W, Robinson
|
|
JL, Hall
|
|
WJ, Brink
|
|
PA, Toivonen
|
|
L, Epstein
|
|
AE, Li
|
|
C, Hu
|
|
D. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome.
|
|
Circulation.
|
|
2004;109:1826–33.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15051644" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15051644</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.schwartz.2003.1120">Schwartz
|
|
PJ, Priori
|
|
SG, Napolitano
|
|
C. How really rare are rare diseases?
|
|
J Cardiovasc Electrophysiol.
|
|
2003;14:1120–1.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/14521668" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14521668</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.schwartz.2001.89">Schwartz
|
|
PJ, Priori
|
|
SG, Spazzolini
|
|
C, Moss
|
|
AJ, Vincent
|
|
GM, Napolitano
|
|
C, Denjoy
|
|
I, Guicheney
|
|
P, Breithardt
|
|
G, Keating
|
|
MT, Towbin
|
|
JA, Beggs
|
|
AH, Brink
|
|
P, Wilde
|
|
AA, Toivonen
|
|
L, Zareba
|
|
W, Robinson
|
|
JL, Timothy
|
|
KW, Corfield
|
|
V, Wattanasirichaigoon
|
|
D, Corbett
|
|
C, Haverkamp
|
|
W, Schulze-Bahr
|
|
E, Lehmann
|
|
MH, Schwartz
|
|
K, Coumel
|
|
P, Bloise
|
|
R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.
|
|
Circulation.
|
|
2001;103:89–95.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11136691" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11136691</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.schwartz.2009.113">Schwartz
|
|
PJ, Spazzolini
|
|
C, Crotti
|
|
L. All LQT3 patients need an ICD: true or false?
|
|
Heart Rhythm.
|
|
2009;6:113–20.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19121811" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19121811</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.seth.2007.1092">Seth
|
|
R, Moss
|
|
AJ, McNitt
|
|
S, Zareba
|
|
W, Andrews
|
|
ML, Qi
|
|
M, Robinson
|
|
JL, Goldenberg
|
|
I, Ackerman
|
|
MJ, Benhorin
|
|
J, Kaufman
|
|
ES, Locati
|
|
EH, Napolitano
|
|
C, Priori
|
|
SG, Schwartz
|
|
PJ, Towbin
|
|
JA, Vincent
|
|
GM, Zhang
|
|
L. Long QT syndrome and pregnancy.
|
|
J Am Coll Cardiol.
|
|
2007;49:1092–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17349890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17349890</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.shimizu.2004.276">Shimizu
|
|
W, Noda
|
|
T, Takaki
|
|
H, Nagaya
|
|
N, Satomi
|
|
K, Kurita
|
|
T, Suyama
|
|
K, Aihara
|
|
N, Sunagawa
|
|
K, Echigo
|
|
S, Miyamoto
|
|
Y, Yoshimasa
|
|
Y, Nakamura
|
|
K, Ohe
|
|
T, Towbin
|
|
JA, Priori
|
|
SG, Kamakura
|
|
S. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome.
|
|
Heart Rhythm.
|
|
2004;1:276–83.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15851169" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15851169</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.skinner.2019.22">Skinner
|
|
JR, Winbo
|
|
A, Abrams
|
|
D, Vohra
|
|
J, Wilde
|
|
AA. Channelopathies that lead to sudden cardiac death: clinical and genetic aspects.
|
|
Heart Lung Circ.
|
|
2019;28:22-30.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30389366" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30389366</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.spazzolini.2009.832">Spazzolini
|
|
C, Mullally
|
|
J, Moss
|
|
AJ, Schwartz
|
|
PJ, McNitt
|
|
S, Ouellet
|
|
G, Fugate
|
|
T, Goldenberg
|
|
I, Jons
|
|
C, Zareba
|
|
W, Robinson
|
|
JL, Ackerman
|
|
MJ, Benhorin
|
|
J, Crotti
|
|
L, Kaufman
|
|
ES, Locati
|
|
EH, Qi
|
|
M, Napolitano
|
|
C, Priori
|
|
SG, Towbin
|
|
JA, Vincent
|
|
GM. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy.
|
|
J Am Coll Cardiol.
|
|
2009;54:832–7.
|
|
[<a href="/pmc/articles/PMC3517782/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3517782</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19695463" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19695463</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.swan.1998.508">Swan
|
|
H, Toivonen
|
|
L, Viitasalo
|
|
M.
|
|
Rate adaptation of QT intervals during and after exercise in children with congenital long QT syndrome.
|
|
Eur Heart J.
|
|
1998;19:508–13.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9568456" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9568456</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.sy.2011.2187">Sy
|
|
RW, van der Werf
|
|
C, Chattha
|
|
IS, Chockalingam
|
|
P, Adler
|
|
A, Healey
|
|
JS, Perrin
|
|
M, Gollob
|
|
MH, Skanes
|
|
AC, Yee
|
|
R, Gula
|
|
LJ, Leong-Sit
|
|
P, Viskin
|
|
S, Klein
|
|
GJ, Wilde
|
|
AA, Krahn
|
|
AD. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands.
|
|
Circulation.
|
|
2011;124:2187–94.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22042885" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22042885</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.tardo.2023.e13015">Tardo
|
|
DT, Peck
|
|
M, Subbiah
|
|
RN, Vandenberg
|
|
JI, Hill
|
|
AP. The diagnostic role of T wave morphology biomarkers in congenital and acquired long QT syndrome: a systematic review.
|
|
Ann Noninvasive Electrocardiol.
|
|
2023;28:e13015.
|
|
[<a href="/pmc/articles/PMC9833360/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9833360</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36345173" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36345173</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.tester.2005.507">Tester
|
|
DJ, Will
|
|
ML, Haglund
|
|
CM, Ackerman
|
|
MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing.
|
|
Heart Rhythm.
|
|
2005;2:507–17.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15840476" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15840476</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.van_langen.2003.141">Van Langen
|
|
IM, Birnie
|
|
E, Alders
|
|
M, Jongbloed
|
|
RJ, Le Marec
|
|
H, Wilde
|
|
AA. The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome.
|
|
J Med Genet.
|
|
2003;40:141–5.
|
|
[<a href="/pmc/articles/PMC1735373/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735373</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12566525" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12566525</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.vincent.1991.498">Vincent
|
|
GM, Jaiswal
|
|
D, Timothy
|
|
KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome.
|
|
Am J Cardiol.
|
|
1991;68:498–503.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/1872278" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1872278</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.vincent.2009.215">Vincent
|
|
GM, Schwartz
|
|
PJ, Denjoy
|
|
I, Swan
|
|
H, Bithell
|
|
C, Spazzolini
|
|
C, Crotti
|
|
L, Piippo
|
|
K, Lupoglazoff
|
|
JM, Villain
|
|
E, Priori
|
|
SG, Napolitano
|
|
C, Zhang
|
|
L. High efficacy of beta-blockers in long-QT syndrome type1; contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures".
|
|
Circulation.
|
|
2009;119:215–21.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19118258" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19118258</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.viskin.2010.1955">Viskin
|
|
S, Postema
|
|
PG, Bhuiyan
|
|
ZA, Rosso
|
|
R, Kalman
|
|
JM, Vohra
|
|
JK, Guevara-Valdivia
|
|
ME, Marquez
|
|
MF, Kogan
|
|
E, Belhassen
|
|
B, Glikson
|
|
M, Strasberg
|
|
B, Antzelevitch
|
|
C, Wilde
|
|
AAM. The response of the QT interval to the brief tachycardia provoked by standing a bedside test for diagnosing long QT syndrome.
|
|
JACC. 2010;55:1955–61.
|
|
[<a href="/pmc/articles/PMC2862092/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2862092</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20116193" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20116193</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.vyas.2006.1385">Vyas
|
|
H, Hejlik
|
|
J, Ackerman
|
|
MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response.
|
|
Circulation.
|
|
2006;113:1385–92.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16534005" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16534005</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.walsh.2022.1500">Walsh
|
|
R, Adler
|
|
A, Amin
|
|
AS, Abiusi
|
|
E, Care
|
|
M, Bikker
|
|
H, Amenta
|
|
S, Feilotter
|
|
H, Nannenberg
|
|
EA, Mazzarotto
|
|
F, Trevisan
|
|
V, Garcia
|
|
J, Hershberger
|
|
RE, Perez
|
|
MV, Sturm
|
|
AC, Ware
|
|
JS, Zareba
|
|
W, Novelli
|
|
V, Wilde
|
|
AAM, Gollob
|
|
MH. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death.
|
|
Eur Heart J.
|
|
2022;43:1500-10.
|
|
[<a href="/pmc/articles/PMC9009401/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9009401</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34557911" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34557911</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.wang.2022.988951">Wang
|
|
M, Peterson
|
|
DR, Pagan
|
|
E, Bagnardi
|
|
V, Mazzanti
|
|
A, McNitt
|
|
S, Rich
|
|
DQ, Seplaki
|
|
CL, Kutyifa
|
|
V, Polonsky
|
|
B, Barsheshet
|
|
A, Kukavica
|
|
D, Rosero
|
|
S, Goldenberg
|
|
I, Priori
|
|
S, Zareba
|
|
W. Assessment of absolute risk of life-threatening cardiac events in long QT syndrome patients.
|
|
Front Cardiovasc Med.
|
|
2022;9:988951.
|
|
[<a href="/pmc/articles/PMC9585302/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9585302</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36277779" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36277779</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.wedekind.2006.129">Wedekind
|
|
H, Bajanowski
|
|
T, Friederich
|
|
P, Breithardt
|
|
G, Wülfing
|
|
T, Siebrands
|
|
C, Engeland
|
|
B, Mönnig
|
|
G, Haverkamp
|
|
W, Brinkmann
|
|
B, Schulze-Bahr
|
|
E.
|
|
Sudden infant death syndrome and long QT syndrome: an epidemiological and genetic study.
|
|
Int J Legal Med.
|
|
2006;120:129–37.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16012827" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16012827</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.westenskow.2004.1834">Westenskow
|
|
P, Splawski
|
|
I, Timothy
|
|
KW, Keating
|
|
MT, Sanguinetti
|
|
MC. Compound mutations: a common cause of severe long-QT syndrome.
|
|
Circulation.
|
|
2004;109:1834–41.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15051636" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15051636</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.wilde.2022.332">Wilde
|
|
AAM, Amin
|
|
AS, Postema
|
|
PG. Diagnosis, management and therapeutic strategies for congenital long QT syndrome.
|
|
Heart.
|
|
2022;108:332-38.
|
|
[<a href="/pmc/articles/PMC8862104/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8862104</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34039680" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34039680</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.zareba.2003.337">Zareba
|
|
W, Moss
|
|
AJ, Daubert
|
|
JP, Hall
|
|
WJ, Robinson
|
|
JL, Andrews
|
|
M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients.
|
|
J Cardiovasc Electrophysiol.
|
|
2003;14:337–41.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12741701" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12741701</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.zeppenfeld.2022.3997">Zeppenfeld
|
|
K, Tfelt-Hansen
|
|
J, de Riva
|
|
M, Winkel
|
|
BG, Behr
|
|
ER, Blom
|
|
NA, Charron
|
|
P, Corrado
|
|
D, Dagres
|
|
N, de Chillou
|
|
C, Eckardt
|
|
L, Friede
|
|
T, Haugaa
|
|
KH, Hocini
|
|
M, Lambiase
|
|
PD, Marijon
|
|
E, Merino
|
|
JL, Peichl
|
|
P, Priori
|
|
SG, Reichlin
|
|
T, Schulz-Menger
|
|
J, Sticherling
|
|
C, Tzeis
|
|
S, Verstrael
|
|
A, Volterrani
|
|
M; ESC Scientific Document Group. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
|
|
Eur Heart J.
|
|
2022;43:3997-4126.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/36017572" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36017572</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="rws.REF.zhang.2000.2849">Zhang
|
|
L, Timothy
|
|
KW, Vincent
|
|
GM, Lehmann
|
|
MH, Fox
|
|
J, Giuli
|
|
LC, Shen
|
|
J, Splawski
|
|
I, Priori
|
|
SG, Compton
|
|
SJ, Yanowitz
|
|
F, Benhorin
|
|
J, Moss
|
|
AJ, Schwartz
|
|
PJ, Robinson
|
|
JL, Wang
|
|
Q, Zareba
|
|
W, Keating
|
|
MT, Towbin
|
|
JA, Napolitano
|
|
C, Medina
|
|
A. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes.
|
|
Circulation.
|
|
2000;102:2849–55.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11104743" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11104743</span></a>]</div></p></li></ul></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK1129_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Alexander J Groffen</span>, PhD<div class="affiliation small">Department of Human Genetics<br />Amsterdam University Medical Center<br />Amsterdam, the Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmumadretsma@nefforg.a" class="oemail">ln.cmumadretsma@nefforg.a</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Hennie Bikker</span>, PhD<div class="affiliation small">Department of Human Genetics<br />Amsterdam University Medical Center<br />Amsterdam, the Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmumadretsma@rekkib.h" class="oemail">ln.cmumadretsma@rekkib.h</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Imke Christiaans</span>, PhD, MD<div class="affiliation small">Department of Genetics<br />University Medical Center Groningen<br />Groningen, the Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.gcmu@snaaitsirhc.i" class="oemail">ln.gcmu@snaaitsirhc.i</a></div></div></div><h3>Publication History</h3><p class="small">Initial Posting: <span itemprop="datePublished">February 20, 2003</span>; Last Update: <span itemprop="dateModified">March 21, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2025, University of Washington, Seattle. GeneReviews is
|
|
a registered trademark of the University of Washington, Seattle. All rights
|
|
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
|
|
hereby granted to reproduce, distribute, and translate copies of content materials for
|
|
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2025 University of
|
|
Washington) are included with each copy; (ii) a link to the original material is provided
|
|
whenever the material is published elsewhere on the Web; and (iii) reproducers,
|
|
distributors, and/or translators comply with the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
|
|
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
|
|
use.</p><p class="small">For more information, see the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
|
|
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div></div><h3>Publisher</h3><p><a href="http://www.washington.edu" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">University of Washington, Seattle</a>, Seattle (WA)</p><h3>NLM Citation</h3><p>Groffen AJ, Bikker H, Christiaans I. Long QT Syndrome Overview. 2003 Feb 20 [Updated 2024 Mar 21]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/gene/loeys-dietz/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/gene/lchad/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobrwsTlongqtsyndromescoringsystemfo"><div id="rws.T.long_qt_syndrome_scoring_system_fo" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Long QT Syndrome: Scoring System for Clinical Diagnosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_scoring_system_fo/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rws.T.long_qt_syndrome_scoring_system_fo_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Findings</th><th id="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Points</th></tr></thead><tbody><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" rowspan="8" scope="rowgroup" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>EKG <sup>1</sup></b>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">QTc <sup>2</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">≥480 ms</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.5</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">460-479 ms</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">450-459 ms (in males)</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">≥480 ms during 4th minute of recovery from exercise stress test</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Torsade de pointes <sup>3</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">T wave alternans</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Notched T wave in 3 leads</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Low heart rate for age <sup>4</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.5</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" rowspan="3" scope="rowgroup" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Clinical history</b>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Syncope <sup>3</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">With stress</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Without stress</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Congenital deafness</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.5</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" rowspan="2" scope="rowgroup" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Family history</b>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Family member(s) with clinical or molecular diagnosis of LQTS <sup>5</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Unexplained sudden cardiac death at age <30 years in immediate family <sup>5</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.5</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genetic finding</b>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Pathogenic variant in a gene known to cause LQTS</td><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.5</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_1 hd_h_rws.T.long_qt_syndrome_scoring_system_fo_1_1_1_2" colspan="4" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Total points:</b> ≤1.0 = low probability of LQTS; 1.5-3.0 = intermediate probability of LQTS; >3.0 = clinical diagnosis of LQTS</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bibr" href="#rws.REF.schwartz.2011.2181" rid="rws.REF.schwartz.2011.2181">Schwartz & Crotti [2011]</a> with modification in <a class="bibr" href="#rws.REF.zeppenfeld.2022.3997" rid="rws.REF.zeppenfeld.2022.3997">Zeppenfeld et al [2022]</a></p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">LQTS = long QT syndrome; QTc = corrected QT</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="rws.TF.1.1"><p class="no_margin">In the absence of medications or disorders known to affect these electrocardiographic features</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="rws.TF.1.2"><p class="no_margin">QTc is calculated by the Bazett formula, where QTc = QT/√RR.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="rws.TF.1.3"><p class="no_margin">Mutually exclusive</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="rws.TF.1.4"><p class="no_margin">Resting heart rate <2nd centile for age</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="rws.TF.1.5"><p class="no_margin">The same family member cannot be used for both criteria.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobrwsTlongqtsyndromephenotypecorrela"><div id="rws.T.long_qt_syndrome_phenotype_correla" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Long QT Syndrome: Phenotype Correlations by Gene</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_phenotype_correla/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rws.T.long_qt_syndrome_phenotype_correla_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Average QTc <sup>1</sup></th><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ST & T Wave Morphology <sup>2</sup></th><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All Cardiac Events <sup>3</sup></th><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Syncope <sup>4</sup></th><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Aborted Cardiac Arrest <sup>5</sup></th><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCD</th><th id="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac Event Trigger <sup>6</sup></th></tr></thead><tbody><tr><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNH2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">480 ms</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bifid (notched) T waves, low-voltage T wave alternans (biphasic)</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">49%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">36%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Auditory stimuli, emotion, exercise, sleep</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNQ1</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Broad-based T wave</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exercise, emotion</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>SCN5A</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">474 ms</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Long ST; high-amplitude & narrow T wave</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td><td headers="hd_h_rws.T.long_qt_syndrome_phenotype_correla_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sleep</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">SCD = sudden cardiac death</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="rws.TF.2.1"><p class="no_margin">Average values from 807, 879, and 237 individuals with <i>KCNH2</i>-, <i>KCNQ1</i>-, and <i>SCN5A</i>-related LQTS, respectively [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="rws.TF.2.2"><p class="no_margin">
|
|
<a class="bibr" href="#rws.REF.tardo.2023.e13015" rid="rws.REF.tardo.2023.e13015">Tardo et al [2023]</a>
|
|
</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="rws.TF.2.3"><p class="no_margin">Cumulative probability of a cardiac event (syncope, aborted cardiac arrest, or sudden death) at age 50 years in a cohort of individuals with <i>KCNH2</i>-, <i>KCNQ1</i>-, and <i>SCN5A</i>-realted LQTS, including 14%-20% of probands and their relatives [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="rws.TF.2.4"><p class="no_margin">Percentage of individuals with one or more syncopal events [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>]</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="rws.TF.2.5"><p class="no_margin">Percentage of individuals with one or more aborted cardiac arrest(s) [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>]</p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="rws.TF.2.6"><p class="no_margin">
|
|
<a class="bibr" href="#rws.REF.schwartz.2001.89" rid="rws.REF.schwartz.2001.89">Schwartz et al [2001]</a>
|
|
</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobrwsTcumulativeprobabilityofcardiac"><div id="rws.T.cumulative_probability_of_cardiac" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Cumulative Probability of Cardiac Events by Age</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1129/table/rws.T.cumulative_probability_of_cardiac/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rws.T.cumulative_probability_of_cardiac_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_1" rowspan="2" scope="rowgroup" colspan="1" headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2" colspan="5" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">% of Persons with ≥1 Cardiac Event <sup>1</sup> by Age <sup>2</sup></th></tr><tr><th headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2" id="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Age 10 years</th><th headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2" id="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 20 years</th><th headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2" id="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 30 years</th><th headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2" id="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 40 years</th><th headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2" id="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 50 years</th></tr></thead><tbody><tr><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNH2</i>
|
|
</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">42%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">46%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">49%</td></tr><tr><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNQ1</i>
|
|
</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">42%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44%</td></tr><tr><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>SCN5A</i>
|
|
</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37%</td><td headers="hd_h_rws.T.cumulative_probability_of_cardiac_1_1_1_2 hd_h_rws.T.cumulative_probability_of_cardiac_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41%</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="rws.TF.3.1"><p class="no_margin">Cardiac events include syncope, aborted cardiac arrest, and sudden cardiac death.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="rws.TF.3.2"><p class="no_margin">Studies from the LQTS Registry including individuals with clinical manifestations, 14%-20% probands and family members with a pathogenic variant (most individuals were on treatment; 52%-60% with beta-blockers) [<a class="bibr" href="#rws.REF.kutyifa.2018.e12537" rid="rws.REF.kutyifa.2018.e12537">Kutyifa et al 2018</a>]</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobrwsTlongqtsyndromegeneticcauses"><div id="rws.T.long_qt_syndrome_genetic_causes" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Long QT Syndrome: Genetic Causes</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rws.T.long_qt_syndrome_genetic_causes_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene <sup>1</sup></th><th id="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of LQTS Attributed to Pathogenic Variants in Gene <sup>2</sup></th><th id="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene Validity Classification <sup>3</sup></th><th id="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS Phenotype(s)</th><th id="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th><th id="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OMIM Phenotype</th></tr></thead><tbody><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNQ1</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30%-35%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/broad-based T waves <sup>4</sup> w/ or w/o atrial fibrillation</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Note: Biallelic variants in <i>KCNQ1</i> cause <a href="/books/n/gene/jln/?report=reader">Jervell and Lange-Nielsen syndrome</a></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/192500" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">192500</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNH2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25%-30%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/bifid T waves <sup>4</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/613688" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">613688</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SCN5A</i> (GoF variants)</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-10%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/long horizontal ST segment <sup>4</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/603830" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">603830</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CACNA1C</i> (GoF variants)</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Some persons have additional features consistent w/<a href="/books/n/gene/timothy/?report=reader">Timothy syndrome</a>.</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/601005" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">601005</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CALM1</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">LQTS or<br />LQTS-CPVT overlap <sup>5</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/616247" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">616247</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CALM2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/616249" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">616249</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CALM3</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/618782" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">618782</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CAV3</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Caveolinopathy is assoc w/a broad spectrum of phenotypes. <sup>6</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/123320" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">123320</a>
|
|
<br />
|
|
<a href="https://omim.org/entry/192600" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">192600</a>
|
|
<br />
|
|
<a href="https://omim.org/entry/606072" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">606072</a>
|
|
<br />
|
|
<a href="https://omim.org/entry/611818" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">611818</a>
|
|
<br />
|
|
<a href="https://omim.org/entry/614321" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">614321</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNJ2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Some persons have additional features consistent w/<a href="/books/n/gene/acpp/?report=reader">Andersen-Tawil syndrome</a>.</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/170390" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">170390</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>TRDN</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Definitive <sup>7</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CPVT-LQTS overlap syndrome <sup>8</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/615441" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">615441</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" rowspan="2" scope="rowgroup" colspan="1" style="text-align:left;vertical-align:middle;"><i>KCNE1</i> <sup>9</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Strong</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Susceptibility to acquired LQTS <sup>6</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Note: Biallelic variants in <i>KCNE1</i> cause <a href="/books/n/gene/jln/?report=reader">Jervell and Lange-Nielsen syndrome</a></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/613695" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">613695</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Limited</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNE2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Strong</td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Susceptibility to acquired LQTS <sup>3</sup></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rws.T.long_qt_syndrome_genetic_causes_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://omim.org/entry/613693" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">613693</a>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Based on <a class="bibr" href="#rws.REF.adler.2020.418" rid="rws.REF.adler.2020.418">Adler et al [2020]</a> and <a href="https://clinicalgenome.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinGen</a></p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CPVT = catecholaminergic polymorphic ventricular tachycardia; GoF = gain-of-function; LQTS = long QT syndrome</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="rws.TF.4.1"><p class="no_margin">Genes are organized first by frequency of causation of LQTS, then strength of ClinGen classification, and then alphabetically.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="rws.TF.4.2"><p class="no_margin">Up to 25% of individuals with LQTS do not have a detectable pathogenic variant in one of the genes in <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromegeneticcauses">table 4</a> [<a class="bibr" href="#rws.REF.ingles.2020.440" rid="rws.REF.ingles.2020.440">Ingles & Semsarian 2020</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="rws.TF.4.3"><p class="no_margin">Gene validity classifications indicate the evidence level for association with the indicated phenotypes. Some genes have different classifications when associated with different phenotypes. Although <i>KCNE2</i> was reported to have disputed evidence of association with LQTS, it was included in <a href="/books/NBK1129/table/rws.T.long_qt_syndrome_genetic_causes/?report=objectonly" target="object" rid-ob="figobrwsTlongqtsyndromegeneticcauses">Table 4</a> because its association with acquired LQTS was strong [<a class="bibr" href="#rws.REF.adler.2020.418" rid="rws.REF.adler.2020.418">Adler et al 2020</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="rws.TF.4.4"><p class="no_margin">
|
|
<a class="bibr" href="#rws.REF.tardo.2023.e13015" rid="rws.REF.tardo.2023.e13015">Tardo et al [2023]</a>
|
|
</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="rws.TF.4.5"><p class="no_margin"><i>CALM1</i>-, <i>CALM2</i>-, and <i>CALM3</i>-related LQTS is associated with an overlap with catecholaminergic polymorphic ventricular tachycardia (CPVT). The OMIM disease entries include both LQTS and CPVT. These phenotypes have been evaluated by ClinGen expert panels as definitive and moderate, respectively [<a class="bibr" href="#rws.REF.adler.2020.418" rid="rws.REF.adler.2020.418">Adler et al 2020</a>, <a class="bibr" href="#rws.REF.walsh.2022.1500" rid="rws.REF.walsh.2022.1500">Walsh et al 2022</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="rws.TF.4.6"><p class="no_margin">During a ClinGen evaluation of gene-disease validity by an expert panel for muscular dystrophies and myopathies, the panel decided to lump all indicated OMIM disease entities as "caveolinopathy" because they found no significant difference in phenotype, inheritance pattern, or molecular mechanism. See <a href="https://search.clinicalgenome.org/kb/genes/HGNC:1529" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri"><i>CAV3</i> ClinGen</a> and <a class="bibr" href="#rws.REF.he.2022.1595" rid="rws.REF.he.2022.1595">He et al [2022]</a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>7. </dt><dd><div id="rws.TF.4.7"><p class="no_margin">See <a href="https://search.clinicalgenome.org/kb/genes/HGNC:12261" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri"><i>TRDN</i> ClinGen</a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>8. </dt><dd><div id="rws.TF.4.8"><p class="no_margin">Biallelic variants in <i>TRDN</i> cause a LQTS-CPVT overlap syndrome. It has been proposed that TRDN-related LQTS be referred to as triadin knockout syndrome because of its recognizable features [<a class="bibr" href="#rws.REF.altmann.2015.2051" rid="rws.REF.altmann.2015.2051">Altmann et al 2015</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>9. </dt><dd><div id="rws.TF.4.9"><p class="no_margin">There is limited evidence for LQTS caused by <i>KCNE1</i> variants in absence of additional QT-prolonging factors, but strong evidence for an association with acquired LQTS (i.e., provoked by non-heritable factors or in combination with pathogenic variants causing QT interval prolongation) [<a class="bibr" href="#rws.REF.adler.2020.418" rid="rws.REF.adler.2020.418">Adler et al 2020</a>].</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobrwsTlongqtsyndromemodeofinheritan"><div id="rws.T.long_qt_syndrome_mode_of_inheritan" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Long QT Syndrome: Mode of Inheritance</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1129/table/rws.T.long_qt_syndrome_mode_of_inheritan/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rws.T.long_qt_syndrome_mode_of_inheritan_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene <sup>1</sup></th><th id="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS Phenotype</th><th id="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mode of<br />Inheritance</th></tr></thead><tbody><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" rowspan="2" scope="rowgroup" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CACNA1C</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/o extracardiac features (See <a href="/books/n/gene/timothy/?report=reader"><i>CACNA1C</i>-Related Disorders</a>.)</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_3" rowspan="8" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Timothy syndrome (See <a href="/books/n/gene/timothy/?report=reader"><i>CACNA1C</i>-Related Disorders</a>.)</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CALM1</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/o extracardiac features</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CALM2</i>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CALM3</i>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CAV3</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/ or w/o extracardiac features</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" rowspan="3" scope="rowgroup" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNE1</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/o extracardiac features</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Susceptibility to acquired LQTS</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/jln/?report=reader">Jervell and Lange-Nielsen syndrome</a>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNE2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Susceptibility to LQTS</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNH2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/o extracardiac features</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNJ2</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/acpp/?report=reader">Andersen-Tawil syndrome</a>
|
|
</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" rowspan="2" scope="rowgroup" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KCNQ1</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/o extracardiac features</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/jln/?report=reader">Jervell and Lange-Nielsen syndrome</a>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SCN5A</i> (GoF variants)</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LQTS w/o extracardiac features</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>TRDN</i>
|
|
</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CPVT-LQTS overlap syndrome</td><td headers="hd_h_rws.T.long_qt_syndrome_mode_of_inheritan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; AR = autosomal recessive; CPVT = catecholaminergic polymorphic ventricular tachycardia; GoF = gain-of-function; LQTS = long QT syndrome</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="rws.TF.5.1"><p class="no_margin">Genes are ordered alphabetically</p></div></dd></dl></dl></div></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript">if (typeof (jQuery) != 'undefined') { (function ($) { $(function () { var min = Math.ceil(1); var max = Math.floor(100000); var randomNum = Math.floor(Math.random() * (max - min)) + min; var surveyUrl = "/projects/Gene/portal/surveys/seqdbui-survey.js?rando=" + randomNum.toString(); $.getScript(surveyUrl, function () { try { ncbi.seqDbUISurvey.init(); } catch (err) { console.info(err); } }).fail(function (jqxhr, settings, exception) { console.info('Cannot load survey script', jqxhr); });; }); })(jQuery); };</script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|